Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy

ABSTRACT

The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.

This application claims priority benefit of U.S. Provisional ApplicationNo. 62/323,163, filed Apr. 15, 2016 and U.S. Provisional Application No.62/473,253, filed Mar. 17, 2017, both of which are incorporated byreference herein in their entirety.

FIELD OF INVENTION

The invention provides gene therapy vectors, such as adeno-associatedvirus (AAV) vectors, expressing the microRNA miR-29 and method of usingthese vectors to reduce and prevent fibrosis in subjects suffering frommuscular dystrophy and to protect muscle fibers from injury, increasemuscle strength.

BACKGROUND

The importance of muscle mass and strength for daily activities, such aslocomotion and breathing, and for whole body metabolism is unequivocal.Deficits in muscle function produce muscular dystrophies (MDs) that arecharacterized by muscle weakness and wasting and have serious impacts onquality of life. The most well-characterized MDs result from mutationsin genes encoding members of the dystrophin-associated protein complex(DAPC). These MDs result from membrane fragility associated with theloss of sarcolemmal-cytoskeleton tethering by the DAPC. DuchenneMuscular Dystrophy (DMD) is one of the most devastating muscle diseasesaffecting 1 in 5000 newborn males.

This application includes two translational approaches to developtreatment for DMD. Fibrotic infiltration is profound in DMD and is asignificant impediment to any potential therapy. It is also important toconsider that gene replacement alone is hampered by the severity offibrosis, already present in very young children with DMD. In fact,muscle biopsies at the usual age of diagnosis, between 4-5 years old,show very significant levels of fibrosis.

DMD is caused by mutations in the DMD gene leading to reductions in mRNAand the absence of dystrophin, a 427 kD sarcolemmal protein associatedwith the dystrophin-associated protein complex (DAPC) (Hoffman et al.,Cell 51(6):919-28, 1987). The DAPC is composed of multiple proteins atthe muscle sarcolemma that form a structural link between theextra-cellular matrix (ECM) and the cytoskeleton via dystrophin, anactin binding protein, and alpha-dystroglycan, a laminin-bindingprotein. These structural links act to stabilize the muscle cellmembrane during contraction and protect against contraction-induceddamage. With dystrophin loss, membrane fragility results in sarcolemmaltears and an influx of calcium, triggering calcium-activated proteasesand segmental fiber necrosis (Straub et al., Curr Opin. Neurol. 10(2):168-75, 1997). This uncontrolled cycle of muscle degeneration andregeneration ultimately exhausts the muscle stem cell population (Saccoet al., Cell, 2010. 143(7): p. 1059-71; Wallace et al., Annu RevPhysiol, 2009. 71: p. 37-57), resulting in progressive muscle weakness,endomysial inflammation, and fibrotic scarring.

Without membrane stabilization from dystrophin or a micro-dystrophin,DMD will manifest uncontrolled cycles of tissue injury and repair andultimately replace lost muscle fibers with fibrotic scar tissue throughconnective tissue proliferation. Fibrosis is characterized by theexcessive deposits of ECM matrix proteins, including collagen andelastin. ECM proteins are primarily produced from cytokines such as TGFβthat is released by activated fibroblasts responding to stress andinflammation. Although the primary pathological feature of DMD ismyofiber degeneration and necrosis, fibrosis as a pathologicalconsequence has equal repercussions. The over-production of fibrotictissue restricts muscle regeneration and contributes to progressivemuscle weakness in the DMD patient. In one study, the presence offibrosis on initial DMD muscle biopsies was highly correlated with poormotor outcome at a 10-year follow-up (Desguerre et al., J NeuropatholExp Neurol, 2009. 68(7): p. 762-7). These results point to fibrosis as amajor contributor to DMD muscle dysfunction and highlight the need todevelop therapies that reduce fibrotic tissue. Most anti-fibrotictherapies that have been tested in mdx mice act to block fibroticcytokine signaling through inhibition of the TGFβ pathway. MicroRNAs(miRNAs) are single-stranded RNAs of 22 nucleotides that mediate genesilencing at the post-transcriptional level by pairing with bases withinthe 3′ UTR of mRNA, inhibiting translation or promoting mRNAdegradation. A seed sequence of 7 bp at the 5′ end of the miRNA targetsthe miRNA; additional recognition is provided by the remainder of thetargeted sequence, as well as its secondary structure. MiRNAs play animportant role in muscle disease pathology and exhibit expressionprofiles that are uniquely dependent on the type of muscular dystrophyin question (Eisenberg et al. Proc Natl Acad Sci USA, 2007. 104(43): p.17016-21). A growing body of evidence suggests that miRNAs are involvedin the fibrotic process in many organs including heart, liver, kidney,and lung (Jiang et al., Proc Natl Acad Sci USA, 2007. 104(43): p.17016-21). Recently, the down-regulation of miR-29 was shown tocontribute to cardiac fibrosis (Cacchiarelli et al., Cell Metab, 2010.12(4): p. 341-51) and reduced expression of miR-29 was geneticallylinked with human DMD patient muscles (Eisenberg et al. Proc Natl AcadSci USA, 2007. 104(43): p. 17016-2). The miR-29 family consists of threefamily members expressed from two bicistronic miRNA clusters. MiR-29a iscoexpressed with miR-29b (miR-29b-1); miR-29c is coexpressed with asecond copy of miR-29b (miR-29b-2). The miR-29 family shares a conservedseed sequence and miR-29a and miR-29b each differ by only one base frommiR-29c. Furthermore, electroporation of miR-29 plasmid (a cluster ofmiR-29a and miR-29b-1) into mdx mouse muscle reduced the expressionlevels of ECM components, collagen and elastin, and strongly decreasedcollagen deposition in muscle sections within 25 days post-treatment(Cacchiarelli et al., Cell Metab, 2010. 12(4): p. 341-51).

Adeno-associated virus (AAV) is a replication-deficient parvovirus, thesingle-stranded DNA genome of which is about 4.7 kb in length including145 nucleotide inverted terminal repeat (ITRs). There are multipleserotypes of AAV. The nucleotide sequences of the genomes of the AAVserotypes are known. For example, the nucleotide sequence of the AAVserotype 2 (AAV2) genome is presented in Srivastava et al., J Virol, 45:555-564 (1983) as corrected by Ruffing et al., J Gen Virol, 75:3385-3392 (1994). As other examples, the complete genome of AAV-1 isprovided in GenBank Accession No. NC_002077; the complete genome ofAAV-3 is provided in GenBank Accession No. NC_1829; the complete genomeof AAV-4 is provided in GenBank Accession No. NC_001829; the AAV-5genome is provided in GenBank Accession No. AF085716; the completegenome of AAV-6 is provided in GenBank Accession No. NC_00 1862; atleast portions of AAV-7 and AAV-8 genomes are provided in GenBankAccession Nos. AX753246 and AX753249, respectively (see also U.S. Pat.Nos. 7,282,199 and 7,790,449 relating to AAV-8); the AAV-9 genome isprovided in Gao et al., J. Virol., 78: 6381-6388 (2004); the AAV-10genome is provided in Mol. Ther., 13(1): 67-76 (2006); and the AAV-11genome is provided in Virology, 330(2): 375-383 (2004). The AAVrh74serotype is described in Rodino-Klapac et al. J. Trans. Med. 5: 45(2007). Cis-acting sequences directing viral DNA replication (rep),encapsidation/packaging and host cell chromosome integration arecontained within the ITRs. Three AAV promoters (named p5, p19, and p40for their relative map locations) drive the expression of the two AAVinternal open reading frames encoding rep and cap genes. The two reppromoters (p5 and p19), coupled with the differential splicing of thesingle AAV intron (e.g., at AAV2 nucleotides 2107 and 2227), result inthe production of four rep proteins (rep 78, rep 68, rep 52, and rep 40)from the rep gene. Rep proteins possess multiple enzymatic propertiesthat are ultimately responsible for replicating the viral genome. Thecap gene is expressed from the p40 promoter and it encodes the threecapsid proteins VP1, VP2, and VP3. Alternative splicing andnon-consensus translational start sites are responsible for theproduction of the three related capsid proteins. A single consensuspolyadenylation site is located at map position 95 of the AAV genome.The life cycle and genetics of AAV are reviewed in Muzyczka, CurrentTopics in Microbiology and Immunology, 158: 97-129 (1992).

AAV possesses unique features that make it attractive as a vector fordelivering foreign DNA to cells, for example, in gene therapy. AAVinfection of cells in culture is noncytopathic, and natural infection ofhumans and other animals is silent and asymptomatic. Moreover, AAVinfects many mammalian cells allowing the possibility of targeting manydifferent tissues in vivo. Moreover, AAV transduces slowly dividing andnon-dividing cells, and can persist essentially for the lifetime ofthose cells as a transcriptionally active nuclear episome(extrachromosomal element). The AAV proviral genome is infectious ascloned DNA in plasmids which makes construction of recombinant genomesfeasible. Furthermore, because the signals directing AAV replication,genome encapsidation and integration are contained within the ITRs ofthe AAV genome, some or all of the internal approximately 4.3 kb of thegenome (encoding replication and structural capsid proteins, rep-cap)may be replaced with foreign DNA such as a gene cassette containing apromoter, a DNA of interest and a polyadenylation signal. The rep andcap proteins may be provided in trans. Another significant feature ofAAV is that it is an extremely stable and hearty virus. It easilywithstands the conditions used to inactivate adenovirus (56° to 65° C.for several hours), making cold preservation of AAV less critical. AAVmay even be lyophilized. Finally, AAV-infected cells are not resistantto superinfection.

Multiple studies have demonstrated long-term (>1.5 years) recombinantAAV-mediated protein expression in muscle. See, Clark et al., Hum GeneTher, 8: 659-669 (1997); Kessler et al., Proc Nat. Acad Sc. USA, 93:14082-14087 (1996); and Xiao et al., J Virol, 70: 8098-8108 (1996). Seealso, Chao et al., Mol Ther, 2:619-623 (2000) and Chao et al., Mol Ther,4:217-222 (2001). Moreover, because muscle is highly vascularized,recombinant AAV transduction has resulted in the appearance of transgeneproducts in the systemic circulation following intramuscular injectionas described in Herzog et al., Proc Natl Acad Sci USA, 94: 5804-5809(1997) and Murphy et al., Proc Natl Acad Sci USA, 94: 13921-13926(1997). Moreover, Lewis et al., J Virol, 76: 8769-8775 (2002)demonstrated that skeletal myofibers possess the necessary cellularfactors for correct antibody glycosylation, folding, and secretion,indicating that muscle is capable of stable expression of secretedprotein therapeutics.

Functional improvement in patients suffering from DMD and other musculardystrophies require both gene restoration and reduction of fibrosis.There is a need for methods of reducing fibrosis that may be paired withgene restoration methods for more effective treatments of DMD and othermuscular dystrophies. miR29 is a potential gene regulator and an idealcandidate for reducing muscle fibrosis.

SUMMARY OF INVENTION

The present invention is directed to gene therapy methods that directlyreduce the three primary components of connective tissue (collagen 1,collagen 3 and fibronectin) by delivering the microRNA miR29. In thissystem, the miR29 binds to the 3′ UTR of the collagen and fibronectingene to down regulate expression. The invention is directed to genetherapy vectors, e.g. AAV, expressing the guide strand of the microRNAmiR29 and method of delivering miR29 to the muscle to reduce and/orprevent fibrosis.

In addition, the invention provides for combination therapies andapproaches for reducing and preventing fibrosis using gene therapyvectors deliver miR-29 to suppress fibrosis along with micro-dystrophinto address the gene defect observed in DMD. As shown in Examples 5-7,the combination treatment resulted in a greater reduction in fibrosis,increased muscle size and increased muscle force.

In one embodiment, the invention provides for a rAAV vector expressingmiR-29. For example, the rAAV vector comprises a polynucleotide sequenceexpressing miR29c such as a nucleotide sequence comprising the miR-29ctarget guide strand of SEQ ID NO: 3, the miR-29c guide strand of SEQ IDNO: 4 and the natural miR-30 back bone and stem loop (SEQ ID NO: 5). Anexemplary polynucleotide sequence comprising the miR-29c cDNA in amiR-30 backbone is set out as SEQ ID NO: 2 (FIG. 1).

An exemplary rAAV of the invention is the pAAV.CMV.Mir29C whichcomprises the nucleotide sequence of SEQ ID NO: 1; wherein the CMVpromoter spans nucleotides 120-526, an EF1a intron spans nucleotides927-1087 and nucleotides 1380-1854, the guide stand of miR-29c spansnucleotide 1257-1284 and the shRNA-miR29-c with primary seed sequencespans nucleotides 1088-1375, and the poly A sequence spans nucleotides1896-2091. In one aspect, the rAAV vectors of the invention are AAV1,AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12or AAV13.

Another exemplary rAAV of the invention is the pAAV.MCK.Mir29C whichcomprises the nucleotide sequence of SEQ ID NO: 12; wherein the MCKenhancer spans nucleotides 190-395, the MHC promoter spans nucleotides396-753, an EF1a intron spans nucleotides 1155-1315 and nucleotides1609-2083, the guide stand of miR-29c spans nucleotide 1487-1512 and theshRNA-miR29-c with primary seed sequence spans nucleotides 1316-1608,and the poly A sequence spans nucleotides 2094-2146. In one aspect, therAAV vectors of the invention are AAV1, AAV2, AAV4, AAV5, AAV6, AAV7,AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13.

In another aspect, the rAAV vectors of the invention may be operablylinked to a muscle-specific control element or an ubiquitous promotersuch as cytomegalovirus (CMV) promoter. For example the muscle-specificcontrol element is human skeletal actin gene element, cardiac actin geneelement, myocyte-specific enhancer binding factor MEF, muscle creatinekinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), MHCK7 (ahybrid version of MHC and MCK), C5-12 (synthetic promoter), murinecreatine kinase enhancer element, skeletal fast-twitch troponin C geneelement, slow-twitch cardiac troponin C gene element, the slow-twitchtroponin I gene element, hypozia-inducible nuclear factors,steroid-inducible element or glucocorticoid response element (GRE).

For example, any of the rAAV vectors of the invention are operablylinked to the muscle-specific control element comprising the MHCenhancer nucleotide sequence of SEQ ID NO: 10 and/or the MHC promotersequence of SEQ ID NO: 11. In addition, any of the rAAV vectors of theinvention are operably linked to the muscle specific control elementcomprising the MHCK7 enhancer nucleotide sequence of SEQ ID NO: 13.

The invention also provides for pharmaceutical compositions (orsometimes referred to herein as simply “compositions”) comprising any ofthe rAAV vectors of the invention.

In another embodiment, the invention provides for methods of producing arAAV vector particle comprising culturing a cell that has beentransfected with any rAAV vector of the invention and recovering rAAVparticles from the supernatant of the transfected cells. The inventionalso provides for viral particles comprising any of the recombinant AAVvectors of the invention.

The invention also provides for methods of producing a mature miR-29nucleotide sequence comprising infecting a host cell with a recombinantAAV vector expressing miR-29 of the invention and expressing a maturemiR-29 in the host cell.

In another embodiment, the invention provides for methods of reducingfibrosis in a subject in need comprising administering a therapeuticallyeffective amount of any rAAV vector of the invention expressing miR-29.For example, any of the rAAV of the invention are administered tosubjects suffering from muscular dystrophy to reduce fibrosis, and inparticular reduces fibrosis in skeletal muscle or in cardiac muscle ofthe subject. These methods may further comprise the step ofadministering a rAAV expressing micro-dystrophin.

For any of the methods, compositions and uses of the invention the term“muscular dystrophy” may be Duchenne muscular dystrophy, Becker musculardystrophy, dysferlin-associated muscular dystrophy, Limb Girdle musculardystrophy including limb girdle muscular dystrophy type 2L or Miyoshimyopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy,dysferlinopathy, dystrophinopathy, myofibrillar myopathy,sarcoglycanopathy, congenital muscular dystrophy, anterior tibialmyopathy, facioscapulohumeral muscular dystrophy, myotonic dystrophy,oculopharngeal muscular dystrophy or ZASP-related myopathy.

“Fibrosis” refers to the excessive or unregulated deposition ofextracellular matrix (ECM) components and abnormal repair processes intissues upon injury including skeletal muscle, cardiac muscle, liver,lung, kidney, and pancreas. The ECM components that are depositedinclude fibronectin and collagen, e.g. collagen 1, collagen 2 orcollagen 3.

In another embodiment, the invention provides for methods of preventingfibrosis in a subject in need comprising administering a therapeuticallyeffective amount of the any recombinant AAV vector of the inventionexpressing miR-29. For example, any of the rAAV of the invention areadministered to subjects suffering from muscular dystrophy to preventfibrosis, e.g. the rAAV of the invention expressing miR-29 areadministered before fibrosis is observed in the subject. In addition,the rAAV of the invention expressing miR-29 are administered to asubject at risk of developing fibrosis, such as those suffering ordiagnosed with dystrophinopathy or muscular dystrophy, e.g. DMD, Beckermuscular dystrophy, Limb Girdle muscular dystrophy or any otherdystrophin associated muscular dystrophy. The rAAV of the invention areadministered to the subject suffering from muscular dystrophy in orderto prevent new fibrosis in these subjects. These methods may furthercomprise the step of administering a rAAV expressing micro-dystrophin.

The invention also provides for methods of increasing muscular forceand/or muscle mass in a subject suffering from muscular dystrophycomprising administering a therapeutically effective amount of any ofthe rAAV vector of the invention expressing miR-29. These methods mayfurther comprise the step of administering a rAAV expressingmicro-dystrophin.

The terms “combination therapy” and “combination treatment” refer toadministration of a rAAV vector of the invention expressing miR-29 andan rAAV vector expressing micro-dystrophin.

In any of the methods of the invention, the subject may be sufferingfrom dystrophinopathy or muscular dystrophysuch as DMD, Becker musculardystrophy, Limb Girdle muscular dystrophy or any otherdystrophin-associated muscular dystrophy.

Any of the foregoing methods of the invention may comprise a furtherstep of administering a rAAV expressing micro-dystrophin. Themicro-dystrophin protein comprises the amino acid sequence of SEQ ID NO:8. The methods may comprises the step of administering a rAAV comprisingthe coding sequence for the micro-dystrophin gene (SEQ ID NO: 7) orcomprising a nucleotide sequence that is at least 85% identical to thenucleotide sequence of SEQ ID NO: 7.

An exemplary rAAV expressing micro-dystrophin of the invention is thepAAV.mck.micro-dystrophin which comprises the nucleotide sequence of SEQID NO: 9 and shown in FIGS. 10 and 11. This rAAV vector comprises theMCK promoter, a chimeric intron sequence, the coding sequence for themicro-dystrophin gene, polyA, ampicillin resistance and the pGEX plasmidbackbone with pBR322 origin or replication. In one aspect, therecombinant AAV vectors of the invention are AAV1, AAV2, AAV4, AAV5,AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12 or AAV13.

The methods of the invention are carried out with rAAV vectors encodingthe micro-dystrophin protein that is, e.g., at least at least 65%, atleast 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% andeven more typically at least 95%, 96%, 97%, 98% or 99% sequence identityto SEQ ID NO: 8, wherein the protein retains micro-dystrophin activity.The micro-dystrophin protein provides stability to the muscle membraneduring muscle contraction, e.g. micro-dystrophin acts as a shockabsorber during muscle contraction.

The methods of the invention are carried out with rAAV vectorsexpressing the micro-dystrophin comprising a nucleotide sequence thathas at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%,83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%,92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or99% sequence identity to SEQ ID NO: 7, and encodes a functionalmicro-dystrophin.

The methods of the invention are carried out with rAAV vectorsexpressing the micro-dystrophin comprising a nucleotide sequence thathybridizes under stringent conditions to the nucleic acid sequence ofSEQ ID NOS: 7, or compliments thereof, and encodes a functionalmicro-dystrophin.

The term “stringent” is used to refer to conditions that are commonlyunderstood in the art as stringent. Hybridization stringency isprincipally determined by temperature, ionic strength, and theconcentration of denaturing agents such as formamide. Examples ofstringent conditions for hybridization and washing are 0.015 M sodiumchloride, 0.0015 M sodium citrate at 65-68° C. or 0.015 M sodiumchloride, 0.0015M sodium citrate, and 50% formamide at 42° C. SeeSambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., ColdSpring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989). Morestringent conditions (such as higher temperature, lower ionic strength,higher formamide, or other denaturing agent) may also be used, however,the rate of hybridization will be affected. In instances whereinhybridization of deoxyoligonucleotides is concerned, additionalexemplary stringent hybridization conditions include washing in 6×SSC0.05% sodium pyrophosphate at 37° C. (for 14-base oligos), 48° C. (for17-base oligos), 55° C. (for 20-base oligos), and 60° C. (for 23-baseoligos).

Other agents may be included in the hybridization and washing buffersfor the purpose of reducing non-specific and/or backgroundhybridization. Examples are 0.1% bovine serum albumin, 0.1%polyvinyl-pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodiumdodecylsulfate, NaDodSO4, (SDS), ficoll, Denhardt's solution, sonicatedsalmon sperm DNA (or other non-complementary DNA), and dextran sulfate,although other suitable agents can also be used. The concentration andtypes of these additives can be changed without substantially affectingthe stringency of the hybridization conditions. Hybridizationexperiments are usually carried out at pH 6.8-7.4, however, at typicalionic strength conditions, the rate of hybridization is nearlyindependent of pH. See Anderson et al., Nucleic Acid Hybridisation: APractical Approach, Ch. 4, IRL Press Limited (Oxford, England).Hybridization conditions can be adjusted by one skilled in the art inorder to accommodate these variables and allow DNAs of differentsequence relatedness to form hybrids.

In another aspect, the rAAV vectors expressing micro-dystrophincomprises the coding sequence of micro-dystrophin gene operably linkedto a muscle-specific control element. For example, the muscle-specificcontrol element is human skeletal actin gene element, cardiac actin geneelement, myocyte-specific enhancer binding factor MEF, muscle creatinekinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), C5-12(synthetic promoter), murine creatine kinase enhancer element, skeletalfast-twitch troponin C gene element, slow-twitch cardiac troponin C geneelement, the slow-twitch troponin I gene element, hypozia-induciblenuclear factors, steroid-inducible element or glucocorticoid responseelement (GRE).

In the methods of administering an rAAV vector expressing miR-29 and anrAAV vector expressing micro-dystrophin, these rAAV vectors may beadministered concurrently, or administered consecutively with the rAAVvector expressing miR29 administered immediately before the rAAVexpressing micro-dystrophin, or administered consecutively with the rAAVvector expressing miR29 is administered immediately after the rAAVexpressing micro-dystrophin. Alternatively, the methods of the inventionare carried out wherein the AAV vector expressing micro-dystrophin isadministered within about 1-5 hours or 5-12 hours or 12 to 15 hours or15 to 24 hours after administering the rAAV expressing miR-29 or themethods of the invention are carried out wherein the AAV vectorexpressing micro-dystrophin is administered within about 1-5 hours or5-12 hours or 12 to 15 hours or 15 to 24 hours before administering therAAV expressing miR-29. Alternatively, the methods of the invention arecarried out wherein the AAV vector expressing micro-dystrophin isadministered within about 1 or 6 or 12 or 24 hours after administeringthe rAAV expressing miR-29 or the methods of the invention are carriedout wherein the AAV vector expressing micro-dystrophin is administeredwithin about 1 or 6 or 12 or 24 hours before administering the rAAVexpressing miR-29.

The invention contemplates administering any of the AAV vectors of theinvention to patients diagnosed with dystrophinopathy or musculardystrophy such as DMD, Becker muscular dystrophy, Limb Girdle musculardystrophy or any other dystrophin associated muscular dystrophy beforefibrosis is observed in the subject or before the muscle force has beenreduced in the subject or before the muscle mass has been reduced in thesubject.

The invention also contemplates administering any of the rAAV of theinvention to a subject suffering from dystrophinopathy or musculardystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle musculardystrophy or any other dystrophin associated muscular dystrophy whoalready has developed fibrosis, in order to prevent new fibrosis inthese subjects. The invention also provides for administering any of therAAV of the invention to the patient suffering from muscular dystrophywho already has reduced muscle force or has reduced muscle mass in orderto protect the muscle from further injury.

In any of the methods of the invention, the rAAV vector are administeredby intramuscular injection or intravenous injection.

In addition, in any of the methods of the invention, the rAAV vector orcomposition is administered systemically. For examples, the rAAV vectoror composition is parentally administration by injection, infusion orimplantation.

In another embodiment, the invention provides for composition comprisingany of the rAAV vectors expressing miR29 for reducing fibrosis in asubject in need. In some embodiments, this composition also comprises arAAV vector expressing micro-dystrophin. For example, this compositioncomprises a rAAV comprising the coding sequence for micro-dystrophingene (SEQ ID NO: 7) or comprises a nucleotide sequence that is at least85% identical to the nucleotide sequence of SEQ ID NO: 7.

In addition, the invention provides for compositions comprising any ofthe recombinant AAV vectors expressing miR29 for preventing fibrosis ina patient suffering from dystrophinopathy or muscular dystrophy such asDMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or anyother dystrophin associated muscular dystrophy. In some embodiments,this composition also comprises a rAAV vector expressingmicro-dystrophin. For example, this composition comprises a rAAVcomprising the coding sequence for micro-dystrophin gene (SEQ ID NO: 7)or may comprising a nucleotide sequence that is at least 85% identicalto the nucleotide sequence of SEQ ID NO: 7.

The invention also provides for compositions comprising any of the rAAVvectors of the invention expressing miR29 for increasing muscular forceand/or muscle mass in a subject suffering from dystrophinopathy ormuscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdlemuscular dystrophy or any other dystrophin associated musculardystrophy. In some embodiments, this composition also comprises a rAAVvector expressing micro-dystrophin. For example, this compositioncomprises a rAAV vector comprising the coding sequence formicro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotide sequencethat is at least 85% identical to the nucleotide sequence of SEQ ID NO:7.

In a further embodiment, the invention provides for compositionscomprising any of the rAAV vectors of the invention expressing miR29 fortreatment of dystrophinopathy muscular dystrophy, such as DMD, Beckermuscular dystrophy, Limb Girdle muscular dystrophy or any otherdystrophin associated muscular dystrophy. In some embodiments, thiscomposition also comprises a rAAV vector expressing micro-dystrophin.For example, this composition comprises a rAAV vector comprising thecoding sequence for micro-dystrophin gene (SEQ ID NO: 7) or comprises anucleotide sequence that is at least 85% identical to the nucleotidesequence of SEQ ID NO: 7.

The compositions of the invention are formulated for intramuscularinjection or intravenous injection. The composition of the invention isalso formulated for systemic administration, such as parentallyadministration by injection, infusion or implantation. In addition, anyof the compositions are formulated for administration to a subjectsuffering from dystrophinopathy or muscular dystrophy such as DMD,Becker muscular dystrophy, Limb Girdle muscular dystrophy or any otherdystrophin associated muscular dystrophy.

In a further embodiment, the invention provides for use of any of therAAV vectors of the invention expressing miR29 for preparation of amedicament for reducing fibrosis in a subject in need. For example, thesubject is in need suffering from dystrophinopathy or musculardystrophy, such as DMD, Becker muscular dystrophy, Limb Girdle musculardystrophy or any other dystrophin associated muscular dystrophy. In someembodiments, the medicament further comprises a rAAV vector expressingmicro-dystrophin. For example, this medicament comprises a rAAVcomprising the coding sequence for micro-dystrophin gene (SEQ ID NO: 7)or comprises a nucleotide sequence that is at least 85% identical to thenucleotide sequence of SEQ ID NO: 7.

In another embodiment, the invention provides for provides for use ofany of the rAAV vectors of the invention expressing miR29 for thepreparation of a medicament for preventing fibrosis in a subjectsuffering from dystrophinopathy or muscular dystrophy, such as DMD,Becker muscular dystrophy, Limb Girdle muscular dystrophy or any otherdystrophin associated muscular dystrophy. In some embodiments, themedicament further comprises a rAAV vector expressing micro-dystrophin.For example, this medicament comprises a rAAV vector comprising thecoding sequence for the micro-dystrophin gene (SEQ ID NO: 7) orcomprising a nucleotide sequence that is at least 85% identical to thenucleotide sequence of SEQ ID NO: 7.

In addition, the invention provides for use of the recombinant AAVvectors of the invention expressing miR29 for the preparation of amedicament for the increasing muscular strength and/or muscle mass in asubject suffering from dystrophinopathy or muscular dystrophy, such asDMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or anyother dystrophin associated muscular dystrophy. In some embodiments, themedicament further comprises a rAAV vector expressing micro-dystrophin.For example, this medicament comprises a rAAV comprising the codingsequence for the micro-dystrophin gene (SEQ ID NO: 7) or comprises anucleotide sequence that is at least 85% identical to the nucleotidesequence of SEQ ID NO: 7.

The invention contemplates use of the any of the AAV vectors of theinvention for the preparation of a medicament for administration to apatient diagnosed with dystrophinopathy or muscular dystrophy, such asDMD, Becker muscular dystrophy, Limb Girdle muscular dystrophy or anyother dystrophin associated muscular dystrophy before fibrosis isobserved in the subject or before the muscle force has been reduced inthe subject or before the muscle mass has been reduced in the subject.

The invention also contemplates use of any of the AAV vectors of theinvention for the preparation of a medicament for administration toadministering any of the rAAV of the invention to a subject sufferingfrom dystrophinopathy or muscular dystrophy, such as DMD, Beckermuscular dystrophy, Limb Girdle muscular dystrophy or any otherdystrophin associated muscular dystrophy who already has developedfibrosis, in order to prevent new fibrosis in these subjects. Theinvention also provides for administering any of the rAAV of theinvention to the patient suffering from muscular dystrophy who alreadyhas reduced muscle force or has reduced muscle mass in order to protectthe muscle from further injury.

The invention also provides for use of the rAAV vectors of the inventionexpressing miR296 for the preparation of a medicament for treatment ofdystrophinopathy or muscular dystrophy, such as DMD, Becker musculardystrophy, Limb Girdle muscular dystrophy or any other dystrophinassociated muscular dystrophy. In some embodiments, the medicamentfurther comprises a rAAV vector expressing micro-dystrophin. Forexample, this medicament comprises a rAAV comprising the coding sequencefor the micro-dystrophin gene (SEQ ID NO: 7) or comprises a nucleotidesequence that is at least 85% identical to the nucleotide sequence ofSEQ ID NO: 7.

In any of the uses of the invention, the medicament is formulated forintramuscular injection. In addition, any of the medicaments may beprepared for administration to a subject suffering from dystrophinopathymuscular dystrophy, such as DMD, Becker muscular dystrophy, Limb Girdlemuscular dystrophy or any other dystrophin associated musculardystrophy.

In addition, any of the medicaments of the invention may be acombination therapy in which the rAAV vectors expressing miR-29 and rAAVvectors expressing micro-dystrophin are administered concurrently, oradministered consecutively with the rAAV vector expressing miR29administered immediately before the rAAV expressing micro-dystrophin, oradministered consecutively with the rAAV vector expressing miR29administered immediately after the rAAV expressing micro-dystrophin.Alternatively, the medicament comprises administration of the AAV vectorexpressing micro-dystrophin administered within about 1-5 hours afteradministering the rAAV expressing miR-29 or the medicament comprises theAAV vector expressing micro-dystrophin administered within about 1-5hours before administering the rAAV expressing miR-29.

BRIEF DESCRIPTION OF DRAWING

FIG. 1 provide a schematic of rAAV vector scAAVCrh.74.CMV.miR29c and thenucleotide sequence of the miR-29c in a natural miR-30 backbone and thenucleotide sequence of the predicted hairpin structure.

FIG. 2A-2D illustrates that injection of miR-29c into muscle reducescollagen throughout the muscle and restores miR-29c expression.

FIG. 3A-3C demonstrates that injection of miR-29c improves absolutemuscle force (panel A) and specific muscle force (panel B) but does notprotect against contraction-induced damage (panel C).

FIG. 4A-4C displays the number of muscle fibers expressionmicro-dystrophin to measure of efficacy of transgene delivery.

FIG. 5A-5C demonstrates that co-delivery of miR-29c withmicro-dystrophin reduces collagen expression (panel A) andfibrosis-induced dystrophin expression.

FIG. 6A-6D illustrates that intramuscular injection ofmiR-29c/micro-dystrophin inhibits extracellular matrix (ECM) inmdx/utrn^(+/−) mice as measured by collagen 1 alpha (panel A), collagen3 alpha (panel B), fibronectin (panel C) and TGF-β (panel D).

FIG. 7A-7C demonstrates the intramuscular injection of miR-29c increasedabsolute force (panel A), normalized specific force (panel B) and addedprotection from contraction-induce damage(panel C) in the muscle.

FIG. 8 illustrates that the miR-29c/μ-dys combination increases musclesize in mice treated at 3 months of age. Sections of treated anduntreated mdx/utrn^(+/−) gastrocnemius muscles stained with picrosiriusRed to stain for collagen are shown. Fibrotic areas are pink and intactmuscle is in green. On the macroscopic level, miR-29c/μ-dys combinationdecreases fibrosis and increases total cross sectional area.

FIG. 9A-F demonstrates that treatment with miR-29c co-delivered withmicro-dystrophin increased muscle hypertrophy and hyperplasia as shownby an increase in the overall weight of the injected gastroc compared toeither one injected alone (panel A), an increase in the an increase inaverage fiber size (panel B), an increase in cross-sectional area of themuscle (panel D; uninjected: 24.6 vs. miR-29c: 26.3 vs. micro-dys: 26.6vs. micro-dys/miR-29c: 33.1) and an increase in the number of musclefibers (panel E) but the number of muscle fibers per unit area was notaffected (panel F). Panel C compares mdx/utrn^(+/−) controls withmiR-29c/μ-dys treated mdx/utrn^(+/−), the average diameter increasedfrom 25.96 to 30.97 μm

FIG. 10A-G demonstrates that early treatment ofAAV.miR-29c/micro-dystrophin combination therapy is more effective atreducing fibrosis and ECM expression. Panel A shows picrosirius redstaining of wild-type, uninjected, AAV.miR-29c, AAV.micro-dystrophin,and AAV.miR-29c/AAV.micro-dystrophin of mice injected at 4-5 wks of agetaken out twelve weeks post-injection. Panel B provides quantificationof picrosirius red staining showing co-treated muscle had a 51.1%reduction in collagen compared to uninjected GAS muscle. Panel Cdemonstrates that qRT-PCR confirms an increase in miR-29c transcriptlevels in the treated cohorts. Semi-quantitative qRT-PCR shows asignificant reduction in collagen I and III (panels d, e), fbn (panel f)and TGF-β1 (panel g) levels in the AAV.miR-29c/AAV.micro-dystrophintreated muscle compared to the contralateral limb and each of the singletherapies Error bars, SEM for n=5 (scAAVrh.74.CMV.miR-29c), n=5(scAAVrh.74.CMV.miR-29c/ssAAVrh.74.MCK.micro-dystrophin), n=6(ssAAVrh.74.MCK.micro-dystrophin), n=9(mdx/utrn^(+/−) mice). 1-way ANOVA(*p<0.05, **p<0.01, ***p<0.001)

FIG. 11 demonstrates early combination therapy restores force andprotects against contraction-induced damage. Measurement of absolute(panel A) and normalized specific force (panel b) following tetaniccontraction in all three treatment injected GAS muscles weresignificantly increased compared to untreated mdx/utrn^(+/−) muscle(panel C). Muscles were then assessed for loss of force followingrepetitive eccentric contractions. Only mice co-treated withmiR-29c/micro-dystrophin and micro-dystrophin alone showed a protectionfrom loss of force compared with untreated mdx/utrn^(+\−) muscles(blue). Two-way analysis of variance demonstrates significance in decaycurves Error bars, SEM for n=5 (rAAVrh.74.CMV.miR-29c), n=6(rAAVrh.74.CMV.miR-29c/rAAVrh.74.MCK.micro-dystrophin), n=5(rAAVrh.74.MCK.micro-dystrophin), n=15 (mdx/utrn+/− mice). 1-way ANOVA(*p<0.05,**p<0.01, ***p<0.001, ****p<0.0001).

FIG. 12 illustrates miR-29c/micro-dystrophin combination treatmentincreases muscle size in mice treated at 1 month of age. Treated anduntreated mdx/utrn^(+/−) GAS muscles were sectioned and staining withpicrosirius Red to stain for collagen. Fibrotic areas are pink andintact muscle is in green. On the macroscopic level,miR-29c/micro-dystrophin combination decreases fibrosis and increasestotal cross sectional area.

FIG. 13A-13G demonstrates that early treatment (at 4-5 weeks) ofAAV.MCK.miR-29c/micro-dystrophin combination therapy is more effectiveat reducing fibrosis and ECM expression. Panel A provide picrosirius redstaining of uninjected and AAV.MCK.miR-29c/AAV.MCK.micro-dystrophin ofmice injected at 4-5 wks of age taken out twelve weeks post-injection.Original magnification, ×20 Panel B provides quantification ofpicrosirius red staining demonstrating co-treated muscle had a 50.9%reduction in collagen compared to untreated GAS muscle Panel C providesqRT-PCR confirming an increase in miR-29c transcript levels in thetreated cohort. Semi-quantitative qRT-PCR shows a significant reductionin Collagen 1A (Col1A; panel D) and Collagen 3A (Col3A; panel E),Fibronectin (Fbn; panel F) and Tgfβ1 (panel G) levels in theAAV.MCK.miR-29c/AAV.micro-dystrophin treated muscle compared to thecontralateral limb therapies. (*p<0.05,****p<0.0001).

FIG. 14A-14G demonstrates that late treatment (treatment at 12 weeks)with AAV.MCK.miR-29c/micro-dystrophin combination therapy is effectiveat reducing fibrosis and ECM expression. Panel A provides picrosiriusred staining of untreated, AAV.MCK.miR-29c andAAV.MCK.miR-29c/AAV.micro-dystrophin twelve weeks post-injection.Original magnification, ×20. Panel B provides quantification ofpicrosirius red staining which demonstrates that co-treated muscle had a30.3% reduction in collagen compared to untreated GAS muscle. Panel Cprovides qRT-PCR confirming an increase in miR-29c transcript levels inthe treated cohorts. Semi-quantitative qRT-PCR demonstrated asignificant reduction in Collagen 1A (Col1A; panel D), Collagen 3A(Col3A; panel E), Fibronectin (Fbn; Panel F) and Tgffβ1 (panel G) levelsin the AAV.miR-29c/AAV.micro-dystrophin treated muscle compared to thecontralateral limb. One-way ANOVA. All data represent mean±SEM.(**p<0.01, ****p<0.0001).

FIG. 15A-15C demonstrates that early combination therapy (treatment at4-5 weeks) restored force and protected against contraction-induceddamage. Measurement of absolute (panel A) and normalized specific force(panel B) following tetanic contraction MCK.miR-29c/micro-dystrophininjected GAS muscles were significantly increased compared to untreatedmdx/utrn^(+/−) muscle. (C) Muscles were then assessed for loss of forcefollowing repetitive eccentric contractions. Mice co-treated withmiR-29c/micro-dystrophin and micro-dystrophin alone showed protectionfrom loss of force compared with untreated mdx/utrn^(+\−) muscles (red).Two-way ANOVA. All data represent mean±SEM (****p<0.0001).

FIG. 16A-16C demonstrates that late combination therapy restored forceand protected against contraction-induced damage. Measurement ofabsolute (panel A) and normalized specific force (panel B) followingtetanic contraction rAAV.MCK.miR-29c and rAAV expressingmicro-dystrophin injected GAS muscles were significantly increasedcompared to untreated mdx/utrn^(+/−) muscle. In Panel C, muscles werethen assessed for loss of force following repetitive eccentriccontractions. Mice co-treated with rAAV.MCK.miR-29c/rAAV expressingmicro-dystrophin showed a protection from loss of force compared withuntreated mdx/utrn^(+\−) muscles (red). Two-way ANOVA. All datarepresent mean±SEM (**p<0.01, ****p<0.0001).

FIG. 17A-17D demonstrates that combination treatment increases musclehypertrophy 3 months post injection. Panel A demonstrates that rAAV.MCK.miR-29c co-delivered with rAAV expressing micro-dystrophin failed toincrease the overall weight of the injected GAS. Panel B demonstratesthat rAAV.MCK.miR-29c/rAAV expressing micro-dystrophin combinationtreatment induced an increase in average fiber size. Comparingmdx/utrn^(+/−) controls with miR-29c/micro-dystrophin treatedmdx/utrn^(+/−), the average diameter increased from 28.96 to 36.03 μm.Panel C shows that co-delivery produced a shift towards wild-type fibersize distribution. Panel D provided the number of muscle fibers per mm²in the miR-29c/micro-dystrophin combination treatment was significantlyless than untreated mice and wild-type (***p<0.01, ****p<0.0001).

FIG. 18A-18B provides the nucleic acid sequence (SEQ ID NO: 1pAAV.CMV.Mir29C) of an exemplary rAAV vector comprising the mature guidestrand of miR-29c (nucleotides 1257-1284) and the natural mi-30 backbone(nucleotides 1088-1375). The construct also comprises the CMV promoter(nucleotides 120-526), two EF1a introns at nucleotides 927-1087 and1380-1854 and a polA at nucleotides 1896-2091.

FIG. 19 provides a schematic of the rAAV vectorpAAV.MCK.micro-dystrophin.

FIG. 20A-20D provides the nucleic acid sequence (SEQ ID NO: 9;pAAV.MCK.micro-dystrophin) of an exemplary rAAV vector expressingmicro-dystrophin.

FIG. 21A-21D provides the nucleotide sequence of the humanmicro-dystrophin nucleotide sequence (SEQ ID NO: 7).

FIG. 22 provides the nucleotide sequence (SEQ ID NO: 12 pAAV.MCK.Mir29C)of an exemplary rAAV vector comprising the mature guide strand ofmiR-29c (nucleotides 1487-1512) and the natural mi-30 backbone(nucleotides 1088-1375). The construct also comprises the MCK enhancer(nucleotides 190-395), MCK promoter (nucleotides 396-753), two EF1aintrons at nucleotides 1155-1315 and 1609-2083 and a polA at nucleotides2094-2148.

DETAILED DESCRIPTION

The present invention provides for gene therapy vectors, e.g. rAAVvectors, overexpressing miR-29 microRNA and methods of reducing andpreventing fibrosis in muscular dystrophy patients. The presentinvention also provides for combination gene therapy methods whichcomprise administering a gene therapy vector expressing miR-29 incombination with a gene therapy vector expressing micro-dystrophin thatis deleted in DMD patients.

Muscle biopsies taken at the earliest age of diagnosis of DMD revealprominent connective tissue proliferation. Muscle fibrosis isdeleterious in multiple ways. It reduces normal transit of endomysialnutrients through connective tissue barriers, reduces the blood flow anddeprives muscle of vascular-derived nutritional constituents, andfunctionally contributes to early loss of ambulation through limbcontractures. Over time, treatment challenges multiply as a result ofmarked fibrosis in muscle. This can be observed in muscle biopsiescomparing connective tissue proliferation at successive time points. Theprocess continues to exacerbate leading to loss of ambulation andaccelerating out of control, especially in wheelchair-dependentpatients.

Without a parallel approach to reduce fibrosis it is unlikely that thebenefits of exon skipping, stop-codon read-through, or gene replacementtherapies can ever be fully achieved. Even small molecules or proteinreplacement strategies are likely to fail without an approach to reducemuscle fibrosis. Previous work in aged mdx mice with existing fibrosistreated with AAV.micro-dystrophin demonstrated that we could not achievefull functional restoration (Rodino-Klapac et al., Human moleculargenetics 22, 4929-4937 (2013)). It is also known that progression of DMDcardiomyopathy is accompanied by scarring and fibrosis in theventricular wall. Micro-RNA delivery is particularly innovative becauseof lack of immune barriers and relative ease of delivery. Micro-RNAs aresmall (˜200 bp) and can therefore be packaged in AAV along with atherapeutic cassette to correct or bypass the genetic defect.

As used herein, the term “AAV” is a standard abbreviation foradeno-associated virus. Adeno-associated virus is a single-stranded DNAparvovirus that grows only in cells in which certain functions areprovided by a co-infecting helper virus. There are currently thirteenserotypes of AAV that have been characterized. General information andreviews of AAV can be found in, for example, Carter, 1989, Handbook ofParvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp.1743-1764, Raven Press, (New York). However, it is fully expected thatthese same principles will be applicable to additional AAV serotypessince it is well known that the various serotypes are quite closelyrelated, both structurally and functionally, even at the genetic level.(See, for example, Blacklowe, 1988, pp. 165-174 of Parvoviruses andHuman Disease, J. R. Pattison, ed.; and Rose, Comprehensive Virology3:1-61 (1974)). For example, all AAV serotypes apparently exhibit verysimilar replication properties mediated by homologous rep genes; and allbear three related capsid proteins such as those expressed in AAV2. Thedegree of relatedness is further suggested by heteroduplex analysiswhich reveals extensive cross-hybridization between serotypes along thelength of the genome; and the presence of analogous self-annealingsegments at the termini that correspond to “inverted terminal repeatsequences” (ITRs). The similar infectivity patterns also suggest thatthe replication functions in each serotype are under similar regulatorycontrol.

An “AAV vector” as used herein refers to a vector comprising one or morepolynucleotides of interest (or transgenes) that are flanked by AAVterminal repeat sequences (ITRs). Such AAV vectors can be replicated andpackaged into infectious viral particles when present in a host cellthat has been transfected with a vector encoding and expressing rep andcap gene products.

An “AAV virion” or “AAV viral particle” or “AAV vector particle” refersto a viral particle composed of at least one AAV capsid protein and anencapsidated polynucleotide AAV vector. If the particle comprises aheterologous polynucleotide (i.e. a polynucleotide other than awild-type AAV genome such as a transgene to be delivered to a mammaliancell), it is typically referred to as an “AAV vector particle” or simplyan “AAV vector”. Thus, production of AAV vector particle necessarilyincludes production of AAV vector, as such a vector is contained withinan AAV vector particle.

AAV

Recombinant AAV genomes of the invention comprise nucleic acid moleculeof the invention and one or more AAV ITRs flanking a nucleic acidmolecule. AAV DNA in the rAAV genomes may be from any AAV serotype forwhich a recombinant virus can be derived including, but not limited to,AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8,AAV-9, AAV-10, AAV-11, AAV-12 and AAV-13. Production of pseudotyped rAAVis disclosed in, for example, WO 01/83692. Other types of rAAV variants,for example rAAV with capsid mutations, are also contemplated. See, forexample, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). Asnoted in the Background section above, the nucleotide sequences of thegenomes of various AAV serotypes are known in the art. To promoteskeletal muscle specific expression, AAV1, AAV6, AAV8 or AAVrh.74 may beused.

DNA plasmids of the invention comprise rAAV genomes of the invention.The DNA plasmids are transferred to cells permissible for infection witha helper virus of AAV (e.g., adenovirus, E1-deleted adenovirus or herpesvirus) for assembly of the rAAV genome into infectious viral particles.Techniques to produce rAAV particles, in which an AAV genome to bepackaged, rep and cap genes, and helper virus functions are provided toa cell, are standard in the art. Production of rAAV requires that thefollowing components are present within a single cell (denoted herein asa packaging cell): a rAAV genome, AAV rep and cap genes separate from(i.e., not in) the rAAV genome, and helper virus functions. The AAV repand cap genes may be from any AAV serotype for which recombinant viruscan be derived and may be from a different AAV serotype than the rAAVgenome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2,AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAVrh.74, AAV-8, AAV-9, AAV-10,AAV-11, AAV-12 and AAV-13. Production of pseudotyped rAAV is disclosedin, for example, WO 01/83692 which is incorporated by reference hereinin its entirety.

A method of generating a packaging cell is to create a cell line thatstably expresses all the necessary components for AAV particleproduction. For example, a plasmid (or multiple plasmids) comprising arAAV genome lacking AAV rep and cap genes, AAV rep and cap genesseparate from the rAAV genome, and a selectable marker, such as aneomycin resistance gene, are integrated into the genome of a cell. AAVgenomes have been introduced into bacterial plasmids by procedures suchas GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA,79:2077-2081), addition of synthetic linkers containing restrictionendonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65-73) orby direct, blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem.,259:4661-4666). The packaging cell line is then infected with a helpervirus such as adenovirus. The advantages of this method are that thecells are selectable and are suitable for large-scale production ofrAAV. Other examples of suitable methods employ adenovirus orbaculovirus rather than plasmids to introduce rAAV genomes and/or repand cap genes into packaging cells.

General principles of rAAV production are reviewed in, for example,Carter, 1992, Current Opinions in Biotechnology, 1533-539; and Muzyczka,1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Variousapproaches are described in Ratschin et al., Mol. Cell. Biol. 4:2072(1984); Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984);Tratschin et al., Mol. Cell. Biol. 5:3251 (1985); McLaughlin et al., J.Virol., 62:1963 (1988); and Lebkowski et al., 1988 Mol. Cell. Biol.,7:349 (1988). Samulski et al. (1989, J. Virol., 63:3822-3828); U.S. Pat.No. 5,173,414; WO 95/13365 and corresponding U.S. Pat. No. 5,658,776; WO95/13392; WO 96/17947; PCT/US98/18600; WO 97/09441 (PCT/US96/14423); WO97/08298 (PCT/US96/13872); WO 97/21825 (PCT/US96/20777); WO 97/06243(PCT/FR96/01064); WO 99/11764; Perrin et al. (1995) Vaccine13:1244-1250; Paul et al. (1993) Human Gene Therapy 4:609-615; Clark etal. (1996) Gene Therapy 3:1124-1132; U.S. Pat. Nos. 5,786,211;5,871,982; and 6,258,595. The foregoing documents are herebyincorporated by reference in their entirety herein, with particularemphasis on those sections of the documents relating to rAAV production.

The invention thus provides packaging cells that produce infectiousrAAV. In one embodiment packaging cells may be stably transformed cancercells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293line). In another embodiment, packaging cells are cells that are nottransformed cancer cells, such as low passage 293 cells (human fetalkidney cells transformed with E1 of adenovirus), MRC-5 cells (humanfetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells(monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).

Recombinant AAV (i.e., infectious encapsidated rAAV particles) of theinvention comprise a rAAV genome. In exemplary embodiments, the genomesof both rAAV lack AAV rep and cap DNA, that is, there is no AAV rep orcap DNA between the ITRs of the genomes. Examples of rAAV that may beconstructed to comprise the nucleic acid molecules of the invention areset out in International Patent Application No. PCT/US2012/047999 (WO2013/016352) incorporated by reference herein in its entirety.

The rAAV may be purified by methods standard in the art such as bycolumn chromatography or cesium chloride gradients. Methods forpurifying rAAV vectors from helper virus are known in the art andinclude methods disclosed in, for example, Clark et al., Hum. GeneTher., 10(6): 1031-1039 (1999); Schenpp and Clark, Methods Mol. Med., 69427-443 (2002); U.S. Pat. No. 6,566,118 and WO 98/09657.

In another embodiment, the invention contemplates compositionscomprising rAAV of the present invention. Compositions of the inventioncomprise rAAV and a pharmaceutically acceptable carrier. Thecompositions may also comprise other ingredients such as diluents andadjuvants. Acceptable carriers, diluents and adjuvants are nontoxic torecipients and are preferably inert at the dosages and concentrationsemployed, and include buffers such as phosphate, citrate, or otherorganic acids; antioxidants such as ascorbic acid; low molecular weightpolypeptides; proteins, such as serum albumin, gelatin, orimmunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;amino acids such as glycine, glutamine, asparagine, arginine or lysine;monosaccharides, disaccharides, and other carbohydrates includingglucose, mannose, or dextrins; chelating agents such as EDTA; sugaralcohols such as mannitol or sorbitol; salt-forming counter ions such assodium; and/or nonionic surfactants such as Tween, pluronics orpolyethylene glycol (PEG).

Titers of rAAV to be administered in methods of the invention will varydepending, for example, on the particular rAAV, the mode ofadministration, the treatment goal, the individual, and the cell type(s)being targeted, and may be determined by methods standard in the art.Titers of rAAV may range from about 1×10⁶, about 1×10⁷, about 1×10⁸,about 1×10⁹, about 1×10¹⁰, about 1×10¹¹, about 1×10¹², about 1×10¹³ toabout 1×10¹⁴ or more DNase resistant particles (DRP) per ml. Dosages mayalso be expressed in units of viral genomes (vg).

Methods of transducing a target cell with rAAV, in vivo or in vitro, arecontemplated by the invention. The in vivo methods comprise the step ofadministering an effective dose, or effective multiple doses, of acomposition comprising a rAAV of the invention to an animal (including ahuman being) in need thereof. If the dose is administered prior todevelopment of a disorder/disease, the administration is prophylactic.If the dose is administered after the development of a disorder/disease,the administration is therapeutic. In embodiments of the invention, aneffective dose is a dose that alleviates (eliminates or reduces) atleast one symptom associated with the disorder/disease state beingtreated, that slows or prevents progression to a disorder/disease state,that slows or prevents progression of a disorder/disease state, thatdiminishes the extent of disease, that results in remission (partial ortotal) of disease, and/or that prolongs survival. An example of adisease contemplated for prevention or treatment with methods of theinvention is FSHD.

Combination therapies are also contemplated by the invention.Combination as used herein includes both simultaneous treatment andsequential treatments. Combinations of methods of the invention withstandard medical treatments (e.g., corticosteroids) are specificallycontemplated, as are combinations with novel therapies.

Administration of an effective dose of the compositions may be by routesstandard in the art including, but not limited to, intramuscular,parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial,intraosseous, intraocular, rectal, or vaginal. Route(s) ofadministration and serotype(s) of AAV components of the rAAV (inparticular, the AAV ITRs and capsid protein) of the invention may bechosen and/or matched by those skilled in the art taking into accountthe infection and/or disease state being treated and the targetcells/tissue(s) that are to express the miR-29 miRNA and/ormicro-dystrophin.

The invention provides for local administration and systemicadministration of an effective dose of rAAV and compositions of theinvention including combination therapy of the invention. For example,systemic administration is administration into the circulatory system sothat the entire body is affected. Systemic administration includesenteral administration such as absorption through the gastrointestinaltract and parental administration through injection, infusion orimplantation.

In particular, actual administration of rAAV of the present inventionmay be accomplished by using any physical method that will transport therAAV recombinant vector into the target tissue of an animal.Administration according to the invention includes, but is not limitedto, injection into muscle, the bloodstream and/or directly into theliver. Simply resuspending a rAAV in phosphate buffered saline has beendemonstrated to be sufficient to provide a vehicle useful for muscletissue expression, and there are no known restrictions on the carriersor other components that can be co-administered with the rAAV (althoughcompositions that degrade DNA should be avoided in the normal mannerwith rAAV). Capsid proteins of a rAAV may be modified so that the rAAVis targeted to a particular target tissue of interest such as muscle.See, for example, WO 02/053703, the disclosure of which is incorporatedby reference herein. Pharmaceutical compositions can be prepared asinjectable formulations or as topical formulations to be delivered tothe muscles by transdermal transport. Numerous formulations for bothintramuscular injection and transdermal transport have been previouslydeveloped and can be used in the practice of the invention. The rAAV canbe used with any pharmaceutically acceptable carrier for ease ofadministration and handling.

The dose of rAAV to be administered in methods disclosed herein willvary depending, for example, on the particular rAAV, the mode ofadministration, the treatment goal, the individual, and the cell type(s)being targeted, and may be determined by methods standard in the art.Titers of each rAAV administered may range from about 1×10⁶, about1×10⁷, about 1×10⁸, about 1×10⁹, about 1×10¹⁰, about 1×10¹¹, about1×10¹², about 1×10¹³, about 1×10¹⁴, or to about 1×10¹⁵ or more DNaseresistant particles (DRP) per ml. Dosages may also be expressed in unitsof viral genomes (vg) (i.e., 1×10⁷ vg, 1×10⁸ vg, 1×10⁹ vg, 1×10¹⁰ vg,1×10¹¹ vg, 1×10¹² vg, 1×10¹³ vg, 1×10¹⁴ vg, 1×10¹⁵ respectively).Dosages may also be expressed in units of viral genomes (vg) perkilogram (kg) of bodyweight (i.e., 1×10¹⁰ vg/kg, 1×10¹¹ vg/kg, 1×10¹²vg/kg, 1×10¹³ vg/kg, 1×10¹⁴ vg/kg, 1×10¹⁵ vg/kg respectively). Methodsfor titering AAV are described in Clark et al., Hum. Gene Ther., 10:1031-1039 (1999).

In particular, actual administration of rAAV of the present inventionmay be accomplished by using any physical method that will transport therAAV recombinant vector into the target tissue of an animal.Administration according to the invention includes, but is not limitedto, injection into muscle, the bloodstream and/or directly into theliver. Simply resuspending a rAAV in phosphate buffered saline has beendemonstrated to be sufficient to provide a vehicle useful for muscletissue expression, and there are no known restrictions on the carriersor other components that can be co-administered with the rAAV (althoughcompositions that degrade DNA should be avoided in the normal mannerwith rAAV). Capsid proteins of a rAAV may be modified so that the rAAVis targeted to a particular target tissue of interest such as muscle.See, for example, WO 02/053703, the disclosure of which is incorporatedby reference herein. Pharmaceutical compositions can be prepared asinjectable formulations or as topical formulations to be delivered tothe muscles by transdermal transport. Numerous formulations for bothintramuscular injection and transdermal transport have been previouslydeveloped and can be used in the practice of the invention. The rAAV canbe used with any pharmaceutically acceptable carrier for ease ofadministration and handling.

For purposes of intramuscular injection, solutions in an adjuvant suchas sesame or peanut oil or in aqueous propylene glycol can be employed,as well as sterile aqueous solutions. Such aqueous solutions can bebuffered, if desired, and the liquid diluent first rendered isotonicwith saline or glucose. Solutions of rAAV as a free acid (DNA containsacidic phosphate groups) or a pharmacologically acceptable salt can beprepared in water suitably mixed with a surfactant such ashydroxpropylcellulose. A dispersion of rAAV can also be prepared inglycerol, liquid polyethylene glycols and mixtures thereof and in oils.Under ordinary conditions of storage and use, these preparations containa preservative to prevent the growth of microorganisms. In thisconnection, the sterile aqueous media employed are all readilyobtainable by standard techniques well-known to those skilled in theart.

The pharmaceutical carriers, diluents or excipients suitable forinjectable use include sterile aqueous solutions or dispersions andsterile powders for the extemporaneous preparation of sterile injectablesolutions or dispersions. In all cases the form must be sterile and mustbe fluid to the extent that easy syringability exists. It must be stableunder the conditions of manufacture and storage and must be preservedagainst the contaminating actions of microorganisms such as bacteria andfungi. The carrier can be a solvent or dispersion medium containing, forexample, water, ethanol, polyol (for example, glycerol, propyleneglycol, liquid polyethylene glycol and the like), suitable mixturesthereof, and vegetable oils. The proper fluidity can be maintained, forexample, by the use of a coating such as lecithin, by the maintenance ofthe required particle size in the case of a dispersion and by the use ofsurfactants. The prevention of the action of microorganisms can bebrought about by various antibacterial and antifungal agents, forexample, parabens, chlorobutanol, phenol, sorbic acid, thimerosal andthe like. In many cases it will be preferable to include isotonicagents, for example, sugars or sodium chloride. Prolonged absorption ofthe injectable compositions can be brought about by use of agentsdelaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating rAAV in therequired amount in the appropriate solvent with various otheringredients enumerated above, as required, followed by filtersterilization. Generally, dispersions are prepared by incorporating thesterilized active ingredient into a sterile vehicle which contains thebasic dispersion medium and the required other ingredients from thoseenumerated above. In the case of sterile powders for the preparation ofsterile injectable solutions, the preferred methods of preparation arevacuum drying and the freeze drying technique that yield a powder of theactive ingredient plus any additional desired ingredient from thepreviously sterile-filtered solution thereof.

Transduction with rAAV may also be carried out in vitro. In oneembodiment, desired target muscle cells are removed from the subject,transduced with rAAV and reintroduced into the subject. Alternatively,syngeneic or xenogeneic muscle cells can be used where those cells willnot generate an inappropriate immune response in the subject.

Suitable methods for the transduction and reintroduction of transducedcells into a subject are known in the art. In one embodiment, cells canbe transduced in vitro by combining rAAV with muscle cells, e.g., inappropriate media, and screening for those cells harboring the DNA ofinterest using conventional techniques such as Southern blots and/orPCR, or by using selectable markers. Transduced cells can then beformulated into pharmaceutical compositions, and the compositionintroduced into the subject by various techniques, such as byintramuscular, intravenous, subcutaneous and intraperitoneal injection,or by injection into smooth and cardiac muscle, using e.g., a catheter.

Transduction of cells with rAAV of the invention results in sustainedexpression of miR-29 or micro-dystrophin. The present invention thusprovides methods of administering/delivering rAAV which express ofmiR-29 and or micro-dystrophin to an animal, preferably a human being.These methods include transducing tissues (including, but not limitedto, tissues such as muscle, organs such as liver and brain, and glandssuch as salivary glands) with one or more rAAV of the present invention.Transduction may be carried out with gene cassettes comprising tissuespecific control elements. For example, one embodiment of the inventionprovides methods of transducing muscle cells and muscle tissues directedby muscle specific control elements, including, but not limited to,those derived from the actin and myosin gene families, such as from themyoD gene family [See Weintraub et al., Science, 251: 761-766 (1990],the myocyte-specific enhancer binding factor MEF-2 [Cserjesi and Olson,Mol Cell Biol 11: 4854-4862 (1990], control elements derived from thehuman skeletal actin gene [Muscat et al., Mol Cell Biol, 7: 4089-4099(1987)], the cardiac actin gene, muscle creatine kinase sequenceelements [See Johnson et al., Mol Cell Biol, 9:3393-3399 (1989)] and themurine creatine kinase enhancer (mCK) element, control elements derivedfrom the skeletal fast-twitch troponin C gene, the slow-twitch cardiactroponin C gene and the slow-twitch troponin I gene: hypoxia-induciblenuclear factors (Semenza et al., Proc Natl Acad Sci USA, 88: 5680-5684(1991)), steroid-inducible elements and promoters including theglucocorticoid response element (GRE) (See Mader and White, Proc. Natl.Acad. Sci. USA 90: 5603-5607 (1993)), and other control elements.

Muscle tissue is an attractive target for in vivo DNA delivery, becauseit is not a vital organ and is easy to access. The inventioncontemplates sustained expression of miRNAs from transduced myofibers.

By “muscle cell” or “muscle tissue” is meant a cell or group of cellsderived from muscle of any kind (for example, skeletal muscle and smoothmuscle, e.g. from the digestive tract, urinary bladder, blood vessels orcardiac tissue). Such muscle cells may be differentiated orundifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytesand cardiomyoblasts.

The term “transduction” is used to refer to the administration/deliveryof the miiR29 guide strand or the coding region of micro-dystrophin to arecipient cell either in vivo or in vitro, via a replication-deficientrAAV of the invention resulting in expression of a miR29 ormicro-dystrophin by the recipient cell.

Thus, the invention provides methods of administering an effective dose(or doses, administered essentially simultaneously or doses given atintervals) of rAAV that encode miR29 and/or micro-dystrophin to apatient in need thereof.

EXAMPLES Example 1 Confirmation of Duchenne Muscular Dystrophy Models

The mdx mouse provides a convenient, yet incomplete, animal model tostudy DMD pathogenesis. This model is a cross of the mdx mouse with aheterozygous knockout of the utrophin gene (mdx:utm++/−), which presentswith increased fibrosis and more faithfully recapitulates the pathologyof human DMD. Mdx mice have a nonsense mutation in exon 23 of DMD thatresults in a relatively mild phenotype and a near-normal life span. By 3weeks of age, the diaphragm and limb muscle of mdx mice develop signs ofendomysial inflammation. These symptoms subside in the limb muscle afterthe mice reach adulthood while the inflammation in the diaphragm musclecontinues to progressively worsen. In mdx mice lacking telomerase,muscular dystrophy progressively worsens with age; mdx mice lackingutrophin (DKO) have a phenotype more characteristic of human DMD withearly onset muscle weakness, severe fibrosis, and premature death.Utrophin, an autosomal paralog of the dystrophin, shares a high degreeof sequence homology that may compensate for the lack of dystrophin inthe mdx mouse in the double KO (dystrophin plus utrophin); a severephenotype with early death is observed. The premature death in the DKOmouse precludes progression of inflammation and fibrosis, but themdx:utrn^(+/−) mouse presents a model with similarities to the humandisease exhibiting a striking degree of fibrosis, and a longer survivalthan the DKO, providing a better model for our proposed translationalstudies. A recent report confirms the use of the mdx:utrn^(+/−) mouse asan ideal model to study fibrosis in the context of DMD. In the presentstudy, increased fibrosis as measured by Sirius red staining wasaccompanied by increased collagen transcript levels and decreased mir29clevels.

Example 2 Delivery of miR29 to DMD Mice Reduces Fibrosis

Preliminary studies have demonstrated that there is a significantincrease in Sirius Red staining for collagen and a decrease in miR-29clevels in human DMD patients and the mdx/utrn^(+/−) mouse. Gene deliveryof miR-29 using muscle specific AAV vectors is potentially safe andefficient. To generate the rAAV vector, referred to herein asrAAVrh.74.CMV.miR29c, the 22 nucleotide miR29c sequence (target strandSEQ ID NO: 3 and guide strand SEQ ID NO: 4) was cloned into a miR-30scaffold driven by a CMV promoter. The expression cassette (SEQ ID NO:2) was cloned into a self-complementary AAV plasmid and packaged usingAAVrh.74, a serotype known to express well in muscle. The miR-29c cDNAwas synthesized using a custom primer containing the miR-29c target(sense) strand, miR-30 stem loop and miR-29c guide (antisense) strand inthe miR-30 backbone. Three bases of the miR-29c sequence were modified.This sequence was then cloned into a self-complementary AAV ITRcontaining plasmid driven by the CMV promoter and polyA sequence.

As shown in FIG. 1, the pAAV.CMV.miR29C plasmid contains the mir29c cDNAin a miR-30 stem loop backbone flanked by AAV2 inverted terminal repeatsequences (ITR). It is this sequence that was encapsidated into AAVrh.74virions. In addition, a few nucleotides with in the miR-29c targetsequence were changed to mimic Watson-crick pairing at this site as inshRNA-miR(luc). According to ShRNA-luc design, the hairpin should beperfectly complementary throughout its length. Plus, the more changes tothe passenger strand, the more likely the elimination of any endogenousmechanism that regulates miR-29 processing that could recognize themiRNA via the stem. The 19^(th) base of the guide strand was modified toa cytosine to mimic the nucleotide that precedes the cleavage site innatural mi-29c sequence and the corresponding base on the other strandwas changed to preserve pairing.

The gene therapy vector scrAAVrh.74.CMV.miR29c (1×10¹¹ vgs) was injectedinto the quadriceps muscle of 3 month old mdx/utrn^(+/−) mice.Quadriceps muscle was analyzed 3 months post-injection by Sirius Redstaining and analyzed by NIH ImageJ software as described in Nevo et al.(PloS One, 6: e18049 (2011). MiR29c, collagen and elastin levels werequantified by RT-PCR. Delivery of miR-29c to young mdx/utrn^(+/−) micesignificantly increases mir-29c levels and a significant reduction inSirius red staining in the quadriceps muscle of 6 month oldmdx/utrn^(+/−) mice (3 months post injection). There was a reduction incollagen and elastin levels in the treated muscles when evaluated byRT-PCR.

Demonstration of increased fibrosis and decreased miR29 expression inthe mdx/utrn^(+/−) mice and dystrophin-deficient patients validates themouse model as being representative of the human disease. Initialresults using AAV-delivered miR29 as an anti-fibrotic therapy suggestthat there is significant beneficial effect with reduction in Sirius Redstaining and collagen and elastin levels, which are key contributors infibrosis.

Example 3 Injection of MiR-29c Reduces Collagen and Restores miR-29c

To determine whether rAAVrh.74.CMV.MiR-29c could reduce fibrosis,12-week-old mdx/utrn^(+\−) mice received an intramuscular injection ofrAAVrh.74.CMV.MiR-29c at 5×10¹¹ vgs to the left gastrocnemius (GAS)muscle. The mice were analyzed at 12 weeks post injection. Picrosiriusred staining revealed a significant decrease in collagen stainingthroughout the GAS muscles (FIG. 2a ) compared to the untreatedcontralateral mdx/utrn+/− GAS muscle. Quantification of the picrosiriusred staining shows that treated muscle had a 18.3% reduction in collagencompared to the untreated muscle (treated—23.3%±1.3 vs.untreated—29.5%±0.7)(FIG. 2b ). To confirm overexpression of miR-29c intreated muscle, total RNA was extracted from the GAS muscle from 24 weekold WT, miR-29c treated and mdx/utrn^(+/−) mice and subjected toquantitative reverse-transcription PCR (qRT-PCR) analysis for miR-29cexpression. The results showed that miR-29c was significantly increasedin the GAS muscle of the treated mice compared to untreated mice (FIG.2d ).

Example 4 MiR-29c Improves Absolute and Specific Muscle Force but doesnot Protect Against Contraction-Induced Damage

Knowing that fibrosis can impact muscle function, we wanted to testwhether reducing fibrosis by increasing expression of MiR-29c couldprotect mdx/utrn^(+/−) muscle from contraction-induced injury andincrease overall force. The functional properties of the gastrocnemiusmuscle from mdx/utrn^(+/−) mice treated with rAAVrh.74.CMV.MiR-29c wereassessed. Twelve weeks post injection, the GAS was isolated to performin vivo force measurements.

The GAS procedure follows the protocol listed in Hakim et al., (MethodsMol Biol. 709: 75-89, 2011) for analyzing transverse abdominal musclephysiology but adapted for the GAS. Briefly, mice were anesthetizedusing ketamine/xylazine mixture. The hind limb skin was removed toexpose the GAS muscle and the Achilles tendon. The distal tendon wasdissected out and a double square knot was tied around the tendon with4-0 suture as close to the muscle as possible, another second doublesquare knot is tied right next to the first knot and then tendon is cut.The exposed muscle was constantly dampened with saline. Mice were thentransferred to a thermal controlled platform and maintained at 37°. Theknee was secured to the platform with a needle through the patellatendon, the tendon suture to the level arm of the force transducer(Aurora Scientific, Aurora, ON, Canada), and the foot was secured withtape. The GAS muscle contractions were elicited by stimulating thesciatic nerve via bipolar platinum electrodes. Once the muscle wasstabilized, the optimal length was determined by incremental stretchingthe muscle until the maximum twitch force was achieved. After a 3-minuterest period, the GAS was stimulated at 50, 100, 150, and 200 Hz,allowing a 1-minute rest period between each stimulus to determinemaximum tetanic force. Muscle length was measured. Following a 5-minuterest, the susceptibility of the GAS muscle to contraction-induced damagewas assessed. After 500 ms of stimulation, the muscle was lengthened by10% of the optimal length. This consisted of stimulating the muscle at150 Hz for 700 ms. After the stimulation, the muscle was returned to theoptimal length. The cycle was repeated every minute for a total of 5cycles. Specific force was calculated by dividing the maximum tetanicforce by the GAS muscle cross sectional area. After the eccentriccontractions, the mice were then euthanized and the GAS muscle wasdissected out, weighed and frozen for analysis.

Each GAS was subjected to a series of repeated eccentric contraction. Bycomparing the force ratio of each contraction versus the firstcontraction revealed that after the fifth contraction untreated muscledecayed to 0.56±0.05 versus treated 0.50±0.04 (p≤0.0001). The injectedgroup showed a slight decrease in the degree of protection compared toWT controls, that decayed to 0.92±0.02 (FIG. 3c ). This data shows thatreducing fibrosis by increasing expression of miR-29c leads to increasein both absolute and specific force but does not significantly protectmuscle from contraction-induced injury.

rAAVrh.74.MiR-29c treated GAS muscle showed significant improvement inabsolute force when compared to untreated mdx/utrn^(+/−) GAS muscle(rAAV.miR-29c—2277±161.7 vs. mdx/utrn^(+/−) untreated—1722±145.7; FIG.3a ), and also normalized specific force in rAAVrh.74.miR-29c treatedGAS muscle specific improvement when compared to untreated GAS muscle(rAAV.miR-29c—204.7±11.7 vs. mdx/utrn^(+/−) untreated—151.6±14.5; FIG.3b ). Force was still significantly reduced when compared to wild-typecontrols (rAAV.miR-29c—204.7±11.7 vs. wild-type—312.0±34.1).

Example 5 Co-Delivery with Micro-Dystrophin Further Reduces Fibrosis

To determine whether miR-29c/micro-dystrophin combined gene therapyapproach would be more beneficial at reducing fibrosis, 12-week-oldmdx/utrn^(+\−) mice received an intramuscular injection ofrAAVrh.74.CMV.MiR-29c at 5×10¹¹ vgs to the left gastrocnemius muscle.The following gene therapy vectors were administered by intramuscularinjection (IM) into the left gastrocnemius (GAS) muscle of 3 month oldmdx/utrn^(+/−) mice, a DMD mouse model: scAAVrh.74.CMV.miR-29c alone,co-delivered with rAAVrh.74.MCK.micro-dystrophin, andrAAVrh.74.MCK.micro-dystrophin alone.

The pAAV.MCK.micro-dystrophin plasmid contains the humanmicro-dystrophin cDNA expression cassette flanked by AAV2 invertedterminal repeat sequences (ITR) as shown in FIG. 10. It is this sequencethat was encapsidated into AAV rh.74 virions. ThepAAV.MCK.micro-dystrophin plasmid was constructed by inserting the MCKexpression cassette driving a codon optimized human micro-dystrophincDNA sequence into the AAV cloning vector as described in Rodino-Klapacet al. (Mol Ther. 2010 January; 18(1):109-17). A MCK promoter/enhancersequence was used to drive muscle-specific gene expression and iscomposed of the mouse MCK core enhancer (206 bp) fused to the 351 bp MCKcore promoter (proximal). After the core promoter, the 53 bp endogenousmouse MCK Exon1 (untranslated) is present for efficient transcriptioninitiation, followed by the SV40 late 16S/19S splice signals (97 bp) anda small 5′UTR (61 bp). The intron and 5′ UTR are derived from plasmidpCMVß (Clontech). The micro-dystrophin cassette has a consensus Kozakimmediately in front of the ATG start and a small 53 bp synthetic polyAsignal for mRNA termination. The human micro-dystrophin cassettecontains the (R4-R23/Δ71-78) domains. The complementary DNA was codonoptimized for human usage and synthesized by GenScript (Piscataway,N.J.).

The mice were analyzed at 12 and 24 weeks post injection. First, thenumber of muscle fibers expressing micro-dystrophin was used to assessthe efficacy of transgene delivery and to make sure we had similarlevels of micro-dystrophin expressed in each group. We found thatmicro-dystrophin was not different between cohorts treated withmicro-dystrophin alone (71.85±2.25%) compared withmiR-29c/micro-dystrophin combination therapy (75.03±1.91%) (FIG. 4).

GAS muscle was analyzed 12 months post-injection to assess collagenaccumulation by Sirius Red staining and subsequent quantification withImageJ. Additional outcomes included miR-29c and collagen transcriptlevels, force measurements in the GAS muscle, fiber diametermeasurements and western blot analysis for proteins involved in muscleregeneration (MyoD, Myogenin). The amount of fibrosis was analyzed bypicrosirius red staining, which revealed a significant decrease incollagen staining throughout the GAS muscles in all treated groups (FIG.5a ) compared to the untreated contralateral mdx/utrn+/− GAS muscle ormicro-dystrophin alone. Quantification of the picrosirius red stainingshows that co-treated muscle had a 40.8% reduction in collagen comparedto the untreated muscle (treated—17.47%±0.75 vs. untreated—29.5%±0.7)(FIG. 5b ). To confirm expression of miR-29c, qRT-PCR was performed onthe GAS muscle and all treatment groups had an increase in miR-29ccompared to untreated muscle (FIG. 5c ).

Analogous to DMD tissue, a significant reduction in miR-29c levels inmdx/utrn^(+/−) muscle was observed which correlated with increasedfibrosis measured by picrosirius red staining. Following 3 months oftreatment with scAAV.miR-29c alone, there was a significant reduction infibrosis (treated-23.5%±1.3 vs. untreated-27.8%±0.6) in the GAS muscle.When co-delivered with micro-dystrophin, further reduction in collagen(41%) was observed by picrosirius red staining (combination treatment:17.47%±0.75 vs. untreated: 29.5%±0.7) (p<0.0001) (FIG. 5b ). To confirmexpression of miR-29c, qRT-PCR was performed on the GAS muscle and alltreatment groups had an increase in miR-29c compared to untreated muscle(FIG. 5b ).

At 24 weeks post-injection, the results were similar to those observed12 weeks post injection. There was a 47% reduction in collagen bypicrosirius red staining compared to the untreated muscle (combinationtreatment: 16.5±1.23 vs. untreated: 31.07±0.93; p<0.0001) and acoincident increase in miR-29c transcript level.

To further validate reduction of collagen observed by picrosirius redstaining, qRT-PCR was performed on the muscle to quantify transcriptlevels of Col1A, Col3A and also another ECM component, fibronectin(Fbn). qRT-PCR analysis detected a decrease in Col1A and Col3A followingeach treatment, however only the cohort treated with bothmicro-dystrophin and miR-29c showed significant reduction (FIGS. 6a and6b ). The analysis revealed that Fbn was significantly reduced only inthe co-treated cohort (FIG. 6c ).

TGF-β1 has been previously shown to be up regulated in dystrophicmuscle, likely playing a role in the initiation of the fibrotic cascade.TGF-β1 is a known pro-fibrotic cytokine that down regulates miR-29c andis responsible for conversion of myoblasts to myofibroblasts with anincrease in collagen and muscle fibrogenesis. qRT-PCR analysis showsthat co-treated muscle had significantly lower levels of TGF-β1 comparedto uninjected muscle and either treatment alone (FIG. 6d ). At 6 monthspost injection, co-treated muscle continued to show reduced Col1A,Col3A, Fbn and TGF-β1 levels, whereas only slight reductions in Col1AmRNA levels in the miR-29 and micro-dystrophin only groups were observed

An increase in specific and absolute force was observed in the muscletreated with miR-29c alone compared to the untreated limb, which whencombined with micro-dystrophin led to absolute and specific force thatwere not significantly different than wild-type. We also observed asignificant increase in gastroc weight in those muscles that wereco-treated.

Initial results using rAAV.miR-29c as an anti-fibrotic therapy suggestthat there is beneficial effect with reduction in collagen levels, a keycontributor in fibrosis. Moreover, when combined with micro-dystrophinto improve membrane stability, miR29 up regulation normalized muscleforce.

Example 6 Further Increase in Absolute Force and Added Protection fromContraction-Induced Damage

Knowing that miR-29-treated muscle had a modest but significant increasein absolute and specific force, the combination therapy of miR-29coverexpression and micro-dystrophin gene replacement impact on musclefunction was investigated. Twelve weeks post injection, we isolated theGAS for which we performed in vivo force measurements. TherAAVrh.74.MiR-29c vector described above in Example 2 and a rAAV

Co-treated rAAVrh.74.MiR-29c and rAAV expressing Micro-Dys treated GASmuscle showed significant improvement in absolute force when compared tountreated mdx/utrn^(+/−) GAS muscle (co-treated—3582.4±79.4 nM vs.mdx/utrn^(+/−) untreated—1722±145.7 nM vs. wild-type—3005±167.3 nM)(FIG. 7), and also normalized specific force inrAAVrh.74.miR-29c/micro-dys treated GAS muscle specific improvement whencompared to untreated GAS muscle (co-treated mice-244.2±6.6 nM/mm² vs.mdx/utrn^(+/−) untreated—151.6±14.5 nM/mm² vs. 312.0±34.1 nM/mm²) (FIG.7). Both absolute and specific force was not significantly differentfrom wild-type controls.

Each GAS was subjected to a series of repeated eccentric contraction. Bycomparing the force ratio of each contraction versus the firstcontraction revealed that after the fifth contraction untreated muscledecayed to 0.54±0.06 versus co-treated 0.66±0.04 (p<0.0001), which canbe contributed to micro-dystrophin since micro-dystrophin alone alsodecayed to 0.66±0.04. The treated group was still significantly lowerthan wild-type that decayed to 0.92±0.02 (FIG. 7c ). Similar findingswere seen at 24 weeks post injection This data shows that reducingfibrosis and gene replacement leads to increase in both absolute andspecific 5force and significantly protects muscle fromcontraction-induced injury.

Example 7 Combination Treatment Increases Muscle Hypertrophy andHyperplasia

MiR-29c co-delivered with micro-dystrophin increased the overall weightof the injected gastroc compared to either one injected alone at threemonths of age (FIG. 8, FIG. 9a ). To investigate the source of increasedmuscle mass, myofiber diameters are measured. miR-29c/μ-dys combinationtreatment demonstrated an increase in average fiber size. Comparingmdx/utrn^(+/−) controls with miR-29c/μ-dys treated mdx/utrn^(+/−), theaverage diameter increased from 25.96 to 30.97 μm (FIG. 9b ). Theco-delivery produced a shift towards wild-type fiber size distribution(FIG. 9c ). Although the average fiber size was increased does notexplain the 30% increase in gross muscle weight. Total cross-sectionalarea of the muscle was also measured. Gastroc muscles from all groupswere full slide scanned and the total area was measured. Musclesco-treated with micro-dys/miR-29c had a significant increase in crosssectional area compared to untreated and either treatment alone(uninjected: 24.6 vs. miR-29c: 26.3 vs. micro-dys: 26.6 vs.micro-dys/miR-29c: 33.1) (FIG. 8, FIG. 9d ).

miR-29c has been reported it to play a role in the myoD/Pax7/myogeninpathway and it was hypothesized that miR-29c may be impactingregeneration and activation of satellite cells (muscle stem cells) todifferentiate in myogenic lineage. To test this, the total number ofmuscle fibers from the full slide scanned images was counted. Anincreased number of muscle fibers following miR-29c/μ-dys combinationtreatment (FIG. 9e ). Finally, given that muscle fiber diameters inmdx/utrn+/− mice are heterogeneous with many small fibers and somehypertrophic fibers, it was determined whether the number of fibers perunit area (cells/mm2) was affected with treatment. miR-29c/μ-dyscombination treatment was not different than wild-type (FIG. 9f ).

Example 8 Early Treatment With Combination Prevents Fibrosis

In view of the potential importance of combinatorial miR-29c andmicro-dystrophin as a prophylactic therapy for DMD, a cohort of youngermdx/utrn^(+/−) mice were treated at 4 weeks of age. Using the sameparadigm as for other groups as described herein, the followingtreatments were compared for efficacy for prevention of fibrosis byintramuscular injection of GAS: scAAVrh.74.CMV.miR-29c alone,ssAAVrh74.MCK.micro-dystrophin+scAAVrh.74.CMV.miR-29c combinationtherapy, or ssAAVrh74.MCK.micro-dystrophin alone at the same dose. Themice were necropsied 12 weeks post injection. A significant decrease incollagen staining throughout the GAS muscles in all treated groupscompared to the untreated contralateral mdx/utrn^(+/−) GAS muscle wasobserved (FIG. 10A). Quantification of the picrosirius red stainingshowed that muscle co-treated with micro-dystrophin/miR-29c had a 51%reduction in collagen compared to the untreated muscle(treated—11.32%±1.18 vs. untreated-23.15%±0.90) (p<0.0001) (FIG. 10) andqRT-PCR confirmed Col1A, Col3A, Fbn and TGF-β1 reduction followingcombinatorial therapy (FIGS. 10D and E).

Example 9 Early Combination Therapy Restores Force and Protects fromContraction-Induced Damage Better than Late Treatment

In vivo force measurement was carried out on the GAS of the mice treatedearly with the combination therapy as described in Example 8. In4-week-old mdx/utrn^(+/−) mice, co-treatment usingmiR-29c/micro-dystrophin showed significant improvement in absoluteforce when compared to untreated mdx/utrn^(+/−) mice and there was nodifference from wild type (co-treated: 2908±129.5 mN vs. untreated:1639.4±116.9 mN vs. wild-type: 3369.73±154.1 mN). Specific force wasalso normalized to wild type levels following combinatorial therapy(co-treated 338.9±22.34 mN/mm2 vs. untreated 184.3±13.42 mN/mm² vs. WT364.3±7.79 mN/mm²) (FIGS. 11A and B and 12).

Next, each GAS was subjected to a series of repeat eccentriccontractions. By comparing the force ratio of each contraction by thefifth contraction, untreated muscle decayed to 0.53±0.04 versusco-treated 0.82±0.04 (p<0.0001). The combinatorial treatment group wasslightly lower than wild type but not significantly different, whichdecayed to 0.93±0.01 (FIG. 11C). These data show that reducing fibrosisand gene replacement lead to increase in both absolute and specificforce and significantly protects muscle from contraction-induced injury.

These experiments suggest that gene replacement should be started in thenewborn period. Efforts are clearly moving in the direction ofidentifying DMD and other muscular dystrophies in the newborn period.The Ohio Newborn Screening Study illustrates the potential foridentification of DMD in newborns using CK 7 Neurol. as a biomarker(>2000 U/L) with DNA confirmation on the same dried blood spot (Mendellet al., Ann. Neurol. 71: 304-313, 2012). This methodology is now beingextended to other states in the USA (PPMD May 16, 2016: Next Steps withNewborn Screening) and in other countries, particularly the UK (UKNational Screening Committee) and China (Perkin Elmer™ launchesscreening in China).

miR-29 has also shown promise as a treatment modality for cardiac,pulmonary, and liver fibrosis. Myocardial infarction in mice and humansis associated with miR-29 down-regulation. Rooij et al. (Proc. Natl.Acad. Sci, USA 105:13027-13032, 2008) demonstrated that exposingfibroblasts to a miR-29b mimic decreased collagen transcripts providinga path for clinical translation for cardiac fibrosis. Subsequent studiesshowed that in a bleomycin-induced pulmonary fibrosis mouse model,attenuation of fibrosis could be achieved using the Sleeping Beauty (SB)transposon system-based delivery of miR-29b.14. Currently, a miR-29bmimic is in a clinical Phase 1 Safety-Tolerability local intradermaltrial in healthy volunteers (miRagen Therapeutics™ MRG-201). Compared tomiR-29 oligonucleotide delivery that would require repeatedadministration related to the half-life of the oligonucleotides, AAVgene therapy could potentially provide a path for single-delivery genetransfer.

Example 10 Treatment with Muscle Specific Expression of miR-29 andMicro-Dystrophin Reduced Fibrosis and ECM Expression

AAV vectors comprising the miR29c sequence and a muscle specificpromoter MCK were also generated and tested as a combination therapywith AAV vectors expressing micro-dystrophin. To generate the rAAVvector, referred to herein as rAAV.MCK.miR29c, the 22 nucleotide miR29csequence (target strand SEQ ID NO: 3 and guide strand SEQ ID NO: 4) wascloned into a miR-30 scaffold driven by a MCK promoter (SEQ ID NO: 11).The expression cassette (SEQ ID NO: 12) was cloned into a singlestranded AAV plasmid and packaged using AAVrh74, a serotype known toexpress well in muscle. The miR-29c cDNA was synthesized using a customprimer containing the miR-29c target (sense) strand, miR-30 stem loopand miR-29c guide (antisense) strand in the miR-30 backbone. Three basesof the miR-29c sequence were modified. This sequence was then clonedinto a single stranded AAV ITR containing plasmid driven by the MCKpromoter and polyA sequence.

The pAAV.MCK.miR29C plasmid contains the mir29c cDNA in a miR-30 stemloop backbone flanked by AAV2 inverted terminal repeat sequences (ITR).It is this sequence that was encapsidated into AAVrh74 virions. Inaddition, a few nucleotides with in the miR-29c target sequence werechanged to mimic Watson-crick pairing at this site as in shRNA-miR(luc).According to ShRNA-luc design, the hairpin should be perfectlycomplementary throughout its length. Plus, the more changes to thepassenger strand, the more likely the elimination of any endogenousmechanism that regulates miR-29 processing that could recognize themiRNA via the stem. The 19^(th) base of the guide strand was modified toa cytosine to mimic the nucleotide that precedes the cleavage site innatural mi-29c sequence and the corresponding base on the other strandwas changed to preserve pairing.

Early treatment of AAV.MCK.miR-29c/micro-dystrophin combination therapywas more effective at reducing fibrosis and ECM expression. 4-5-week-oldmdx/utrn^(+\−) mice received an intramuscular injection ofrAAVrh.74.MCK.MiR-29c and rAAVrh74.MCK.micro-dystrophin at 5×10¹¹ vgs tothe left gastrocnemius muscle as described in Example 5. The muscleswere harvested twelve weeks post injection. Picrosirius red staining ofmuscle harvested from uninjected and mice injected with combinationtherapy of rAAV.MCK.miR-29c/rAAV.MCK.micro-dystrophin showed co-treatedmuscle had a 50.9% reduction in collagen compared to untreated GASmuscle (See FIGS. 13a and 13b ). qRT-PCR confirmed an increase inmiR-29c transcript levels in the treated cohort (FIG. 13c ).Semi-quantitative qRT-PCR showed a significant reduction in Collagen A1and Collagen 3A (FIG. 13d, e ), Fibronectin (FIG. 13f ) and Tgfβ1 (FIG.13g ) levels in the AAV.MCK.miR-29c/AAV.micro-dystrophin treated musclecompared to the contralateral limb therapies. (*p<0.05,****p<0.0001).Late treatment of AAV.MCK.miR-29c/micro-dystrophin combination therapyis effective at reducing fibrosis and ECM expression. Three month oldmdx/utrn^(+\−) mice received an intramuscular injection ofrAAVrh.74.MCK.MiR-29c and rAAVrh.74.MCK.micro-dystrophin at 5×10¹¹ vgsto the left gastrocnemius muscle as described in Example 5. The muscleswere harvested twelve weeks post injection. Picrosirius red staining ofuntreated, AAV.MCK.miR-29c and AAV.MCK.miR-29c/AAV.micro-dystrophintreated muscle showed co-treated muscle had a 30.3% reduction incollagen compared to untreated GAS muscle (See FIGS. 14a and 14b )qRT-PCR confirmed an increase in miR-29c transcript levels in thetreated cohorts (FIG. 14c ). Semi-quantitative qRT-PCR shows asignificant reduction in Collagen 1A and Collagen 3A (FIG. 14d, e ),Fibronectin (FIG. 14f ) and Tgfβ1 (FIG. 14G) levels in theAAV.miR-29c/AAV.micro-dystrophin treated muscle compared to thecontralateral limb. One-way ANOVA. All data represent mean±SEM.(**p<0.01, ****p<0.0001).

Example 11 Early Combination Therapy Restores Force and Protects fromContraction-Induced Damage Better than Late Treatment

In vivo force measurement was carried out on the GAS of the mice treatedearly with the muscle-specific expression of miR-29 andmicro-dystrophin. as described in Examples 8 and 9. In 4-week-oldmdx/utrn^(+/−) mice, co-treatment using rAAV.MCK.miR-29c/and rAAVexpressing micro-dystrophin showed significant improvement in absoluteforce when compared to untreated mdx/utrn^(+/−) mice and there was nodifference from wild type (FIG. 15a ). Specific force was alsonormalized to wild type levels following combination therapy (FIG. 15b).

Muscles were then assessed for loss of force following repetitiveeccentric contractions as described in Example 9. Mice co-treated withrAAV.MCK.miR-29c/rAAV.MCK.micro-dystrophin and rAAV.MCK.micro-dystrophinalone showed a protection from loss of force compared with untreatedmdx/utrn^(+\−) muscles (FIG. 15c ).

In 12-week-old mdx/utrn^(+/−) mice, co-treatment usingrAAV.MCK.miR-29c/and rAAV expressing micro-dystrophin restored force andprotected against contraction-induced damage. Measurement of absolute(FIG. 16a ) and normalized specific force (FIG. 16b ) following tetaniccontraction rAAV.MCK.miR-29c and rAAV expressing micro-dystrophininjected GAS muscles were significantly increased compared to untreatedmdx/utrn^(+/−) muscle. Subsequently, muscles were assessed for loss offorce following repetitive eccentric contractions as described inExample 9. Mice co-treated with MCK.miR-29c/micro-dystrophin showed aprotection from loss of force compared with untreated mdx/utrn^(+\−)muscles (FIG. 16c ). These data show that reducing fibrosis and genereplacement lead to increase in both absolute and specific force andsignificantly protects muscle from contraction-induced injury.

Example 12 Early Combination Treatment Increases Muscle Hypertrophy andHyperplasia

Co-delivery of rAAV.MCK.miR-29 with rAAV expressing micro-dystrophin didnot increase overall weight of the injected gastroc compared to eitherone injected alone at three months post-injection (FIG. 17a ). Myofiberdiameters were also measured. miR-29c/micro-dystrophin combinationtreatment demonstrated an increase in average fiber size. Comparingmdx/utrn^(+/−) controls with miR-29c/micro-dystrophin treatedmdx/utrn^(+/−), the average diameter increased from 28.96 to 36.03 μm(FIG. 17b ). The co-delivery produced a shift towards wild-type fibersize distribution (FIG. 17c ). The number of muscle fibers per mm² inthe miR-29c/micro-dystrophin combination treatment was significantlyless than untreated mice and wild-type (FIG. 17d ; ***p<0.01,****p<0.0001).

REFERENCES

-   1. Hoffman, E. P., Brown, R. H., Jr. & Kunkel, L. M. Dystrophin: the    protein product of the Duchenne muscular dystrophy locus. Cell 51,    919-928 (1987).-   2. Straub, V. & Campbell, K. P. Muscular dystrophies and the    dystrophin-glycoprotein complex. Curr Opin Neurol 10, 168-175    (1997).-   3. Sacco, A., et al. Short telomeres and stem cell exhaustion model    Duchenne muscular dystrophy in mdx/mTR mice. Cell 143, 1059-1071    (2010).-   4. Wallace, G. Q. & McNally, E. M. Mechanisms of muscle    degeneration, regeneration, and repair in the muscular dystrophies.    Annu Rev Physiol 71, 37-57 (2009).-   5. Zhou, L. & Lu, H. Targeting fibrosis in Duchenne muscular    dystrophy. J Neuropathol Exp Neurol 69, 771-776 (2010).-   6. Desguerre, I., et al. Endomysial fibrosis in Duchenne muscular    dystrophy: a marker of poor outcome associated with macrophage    alternative activation. J Neuropathol Exp Neurol 68, 762-773 (2009).-   7. Kim, J., et al. microRNA-directed cleavage of ATHB15 mRNA    regulates vascular development in Arabidopsis inflorescence stems.    Plant J 42, 84-94 (2005).-   8. Ambros, V. MicroRNA pathways in flies and worms: growth, death,    fat, stress, and timing. Cell 113, 673-676 (2003).-   9. Eisenberg, I., et al. Distinctive patterns of microRNA expression    in primary muscular disorders. Proc Natl Acad Sci USA 104,    17016-17021 (2007).-   10. Jiang, X., Tsitsiou, E., Herrick, S. E. & Lindsay, M. A.    MicroRNAs and the regulation of fibrosis. FEBS J 277, 2015-2021    (2010).-   11. van Rooij, E., et al. Dysregulation of microRNAs after    myocardial infarction reveals a role of miR-29 in cardiac fibrosis.    Proc Natl Acad Sci USA 105, 13027-13032 (2008).-   12. Cacchiarelli, D., et al. MicroRNAs involved in molecular    circuitries relevant for the Duchenne muscular dystrophy    pathogenesis are controlled by the dystrophin/nNOS pathway. Cell    Metab 12, 341-351 (2010).-   13. DiPrimio, N., McPhee, S. W. & Samulski, R. J. Adeno-associated    virus for the treatment of muscle diseases: toward clinical trials.    Curr Opin Mol Ther 12, 553-560 (2010).-   14. Mendell, J. R., et al. Sustained alpha-sarcoglycan gene    expression after gene transfer in limb-girdle muscular dystrophy,    type 2D. Ann Neurol 68, 629-638 (2010).-   15. Mendell, J. R., et al. Limb-girdle muscular dystrophy type 2D    gene therapy restores alpha-sarcoglycan and associated proteins. Ann    Neurol 66, 290-297 (2009).-   16. Mendell, J. R., et al. A phase 1/2a follistatin gene therapy    trial for becker muscular dystrophy. Molecular therapy: the journal    of the American Society of Gene Therapy 23, 192-201 (2015).-   17. Carnwath, J. W. & Shotton, D. M. Muscular dystrophy in the mdx    mouse: histopathology of the soleus and extensor digitorum longus    muscles. J Neurol Sci 80, 39-54 (1987).-   18. Coulton, G. R., Morgan, J. E., Partridge, T. A. & Sloper, J. C.    The mdx mouse skeletal muscle myopathy: I. A histological,    morphometric and biochemical investigation. Neuropathol Appl    Neurobiol 14, 53-70 (1988).-   19. Cullen, M. J. & Jaros, E. Ultrastructure of the skeletal muscle    in the X chromosome-linked dystrophic (mdx) mouse. Comparison with    Duchenne muscular dystrophy. Acta Neuropathol 77, 69-81 (1988).-   20. Dupont-Versteegden, E. E. & McCarter, R. J. Differential    expression of muscular dystrophy in diaphragm versus hindlimb    muscles of mdx mice. Muscle Nerve 15, 1105-1110 (1992).-   21. Stedman, H. H., et al. The mdx mouse diaphragm reproduces the    degenerative changes of Duchenne muscular dystrophy. Nature 352,    536-539 (1991).-   22. Deconinck, A. E., et al. Utrophin-dystrophin-deficient mice as a    model for Duchenne muscular dystrophy. Cell 90, 717-727 (1997).-   23. Grady, R. M., et al. Skeletal and cardiac myopathies in mice    lacking utrophin and dystrophin: a model for Duchenne muscular    dystrophy. Cell 90, 729-738 (1997).-   24. Love, D. R., et al. An autosomal transcript in skeletal muscle    with homology to dystrophin. Nature 339, 55-58 (1989).-   25. Tinsley, J. M., et al. Primary structure of dystrophin-related    protein. Nature 360, 591-593 (1992).-   26. Tinsley, J., et al. Expression of full-length utrophin prevents    muscular dystrophy in mdx mice. Nat Med 4, 1441-1444 (1998).-   27. Squire, S., et al. Prevention of pathology in mdx mice by    expression of utrophin: analysis using an inducible transgenic    expression system. Hum Mol Genet 11, 3333-3344 (2002).-   28. Rafael, J. A., Tinsley, J. M., Potter, A. C., Deconinck, A. E. &    Davies, K. E. Skeletal muscle-specific expression of a utrophin    transgene rescues utrophin-dystrophin deficient mice. Nat Genet 19,    79-82 (1998).-   29. Zhou, L., et al. Haploinsufficiency of utrophin gene worsens    skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci    264, 106-111 (2008).-   30. Gutpell, K. M., Hrinivich, W. T. & Hoffman, L. M. Skeletal    Muscle Fibrosis in the mdx/utrn+/− Mouse Validates Its Suitability    as a Murine Model of Duchenne Muscular Dystrophy. PloS one 10,    e0117306 (2015).-   31. Rodino-Klapac, L. R., et al. Micro-dystrophin and follistatin    co-delivery restores muscle function in aged DMD model. Human    molecular genetics 22, 4929-4937 (2013).-   32. Cushing, L., et al. MIR-29 is a Major Regulator of Genes    Associated with Pulmonary Fibrosis. Am J Respir Cell Mol Biol    (2010).-   33. Roderburg, C., et al. Micro-RNA profiling reveals a role for    miR-29 in human and murine liver fibrosis. Hepatology 53, 209-218    (2011).-   34. Nevo, Y., et al. The Ras antagonist, farnesylthiosalicylic acid    (FTS), decreases fibrosis and improves muscle strength in dy/dy    mouse model of muscular dystrophy. PloS one 6, e18049 (2011).-   35. Rodino-Klapac, L. R., et al. A translational approach for limb    vascular delivery of the micro-dystrophin gene without high volume    or high pressure for treatment of Duchenne muscular dystrophy. J    Transl Med 5, 45 (2007).-   36. Mulieri, L. A., Hasenfuss, G., Ittleman, F., Blanchard, E. M. &    Alpert, N. R. Protection of human left ventricular myocardium from    cutting injury with 2,3-butanedione monoxime. Circ Res 65, 1441-1449    (1989).-   37. Rodino-Klapac, L. R., et al. Persistent expression of    FLAG-tagged micro dystrophin in nonhuman primates following    intramuscular and vascular delivery. Molecular therapy: the journal    of the American Society of Gene Therapy 18, 109-117 (2010).-   38. Grose, W. E., et al. Homologous recombination mediates    functional recovery of dysferlin deficiency following AAV5 gene    transfer. PloS one 7, e39233 (2012).-   39. Liu, M., et al. Adeno-associated virus-mediated microdystrophin    expression protects young mdx muscle from contraction-induced    injury. Mol Ther 11, 245-256 (2005).

What is claimed:
 1. A recombinant AAVrh74 vector comprising the nucleicsequences of SEQ ID NO: 3 or SEQ ID NO:
 4. 2. The recombinant AAVrh74vector of claim 1 comprising a) the nucleotide sequence of SEQ ID NO: 2,b) the nucleotide sequence of SEQ ID NO: 1 or c) the nucleotide sequenceof SEQ ID NO:
 12. 3. The recombinant AAV vector of claim 1 wherein thepolynucleotide sequence is operably linked to a muscle-specific controlelement.
 4. The recombinant AAV vector of claim 3 wherein themuscle-specific control element is cytomegalovirus (CMV) promoter, humanskeletal actin gene element, cardiac actin gene element,myocyte-specific enhancer binding factor mef, muscle creatine kinase(MCK), truncated MCK (tMCK), myosin heavy chain (MHC), MHCK7, C5-12,murine creatine kinase enhancer element, skeletal fast-twitch troponin cgene element, slow-twitch cardiac troponin c gene element, theslow-twitch troponin i gene element, hypoxia-inducible nuclear factors,steroid-inducible element or glucocorticoid response element (gre). 5.The recombinant AAV vector of claim 3 wherein the muscle-specificcontrol element comprises the nucleotide sequence of SEQ ID NO: 10, SEQID NO: 11 or SEQ ID NO:
 13. 6. A composition comprising the recombinantAAV vector of claim
 1. 7. A method of treating muscular dystrophycomprising administering a therapeutically effective amount of thecomposition of claim
 6. 8. A method of reducing or preventing fibrosisin a subject suffering from muscular dystrophy comprising administeringa therapeutically effective amount of the composition of claim
 6. 9. Amethod of preventing fibrosis in a patient suffering from musculardystrophy comprising administering a therapeutically effective amount ofthe composition of claim
 6. 10. A method of increasing muscular force ormuscle mass in a subject suffering from muscular dystrophy comprisingadministering a therapeutically effective amount of the composition ofclaim
 6. 11. The method claim 7 wherein the muscular dystrophy isDuchenne muscular dystrophy or Limb Girdle muscular dystrophy.
 12. Themethod of claim 7 wherein the recombinant AAV vector or the compositionis administered by intramuscular injection.
 13. The method of claim 7wherein the recombinant AAV vector or the composition is administeredsystemically.
 14. The method of claim 13, where the recombinant AAVvector or the composition is parenterally administered by injection,infusion or implantation.
 15. The method of claim 7, wherein therecombinant AAV vector of composition is administered before fibrosis isobserved in the subject or before muscle force is reduced in the subjector before muscle mass is reduced in the subject.
 16. A method ofproducing a mature microRNA polynucleotide sequence comprising infectinga host cell with a recombinant AAV vector claim 1 and expressing amature microRNA polynucleotide in the host cell.
 17. The recombinant AAVvector of claim 2 wherein the polynucleotide sequence is operably linkedto a muscle-specific control element.
 18. The recombinant AAV vector ofclaim 17 wherein the muscle-specific control element is cytomegalovirus(CMV) promoter, human skeletal actin gene element, cardiac actin geneelement, myocyte-specific enhancer binding factor mef, muscle creatinekinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), MHCK7,C5-12, murine creatine kinase enhancer element, skeletal fast-twitchtroponin c gene element, slow-twitch cardiac troponin c gene element,the slow-twitch troponin i gene element, hypoxia-inducible nuclearfactors, steroid-inducible element or glucocorticoid response element(gre).
 19. The recombinant AAV vector of claim 17 wherein themuscle-specific control element comprises the nucleotide sequence of SEQID NO: 10, SEQ ID NO: 11 or SEQ ID NO:
 13. 20. A composition comprisingthe recombinant AAV vector of claim 2.